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Gene regulation by estrogen (E2) plays an important role in mediating
physiological responses in normal and disease states. Estrogen receptors (ERs)
facilitate these responses by at least two genomic modes of action: (1) binding
directly to estrogen response elements (EREs) or (2) binding indirectly to DNA
through transcription factors (like AP-1). Although the ERE pathway is well studied,
little is known about the mechanism of E2-dependent actions through this indirect
pathway (e.g., ER/AP-1 pathway).
Using an unbiased proteomic approach, that utilizes affinity purification and
iTRAQ labeling, I examine the composition of AP-1 complexes in order to better
understand the foundation of ER tethering. The results from this analysis identify
several AP-1 and non-AP-1 transcription factors associated with E2-responsive AP-1
sites. My results also identify putative coregulators that may play a role in mediating
ER/AP-1 responses in vivo.
In further studies, I characterize the genomic interplay between E2-signaling
and the AP-1 regulator, Jun N-terminal Kinase 1 (JNK1). Interestingly, I show that
JNK1 binds to discrete regions of the genome in an E2-regulated manner and correlate
these binding events with ERα occupancy. I also define the transcription factors
responsible for tethering JNK1 to promoter regions. These results reveal the emerging
theme that MAP kinases (like JNK1) can form stable, chromatin-associated
complexes. Furthermore, I describe the necessity of JNK1 activity in mediating E2-

dependent transcriptional outcomes in breast cancer cells and demonstrate the
importance of JNK1 in E2-dependent tumor cell growth. Finally, I show that JNK1
can phosphorylate coactivators involved in E2-dependent complexes, as well as
histone H3. Modification of these factors may play a role in facilitating E2-dependent
transcriptional responses in vivo. My results establish a new paradigm for estrogen
signaling which now includes JNK1 as an E2-dependent coregulator.
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CHAPTER 1
Transcriptional Regulation by Estrogens Through the
AP-1 Pathway: An Overview
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Physiology of Estrogens
It is well-known that estrogens, such as 17β-estradiol (E2), play pivotal roles
in the regulation of sexual development and fertility in both males and females (Couse
and Korach, 1999a; Couse and Korach, 1999b; Nef and Parada, 2000; O'Donnell et al.,
2001). Estrogens also regulate metabolic processes in fat, liver, and bone tissues
(DeCherney, 1993; Vaananen and Harkonen, 1996). In addition to these roles in
normal physiological processes, estrogens also play pivotal roles in many disease
states. For example, estrogens can act as potent mitogens in some cancers (e.g.,
breast, uterine) causing hormone-dependent growth and proliferation (Foster et al.,
2001; Prall et al., 1998; Sommer and Fuqua, 2001). A variety of synthetic estrogen
antagonists ("antiestrogens") have been developed and are used clinically to reverse
the mitogenic action of estrogens in estrogen-dependent cancers (e.g., Tamoxifen,
Tam; Raloxifene, Ral). Interestingly, these same compounds may have estrogen-like
agonistic activities in some tissues (e.g., bone, endometrium), functioning more like
tissue- or cell type-specific "selective estrogen receptor modulators" (SERMs) than
pure antagonists (Harper and Walpole, 1967; McDonnell et al., 2002; Paech et al.,
1997; Webb et al., 1995). Gaining a greater understanding of the molecular actions of
estrogens and SERMs will aid in the development of new compounds that are even
more effective in the treatment of breast cancers.

Estrogen Receptors
The molecular actions of estrogens are mediated through estrogen receptor
(ER) proteins which bind the hormones, dimerize, and regulate the transcription of
estrogen-responsive genes. ERs exist as two isoforms, ERα and ERβ (Warner et al.,
1999), which are members of a conserved superfamily of nuclear receptors that
function as transcription factors (Mangelsdorf et al., 1995). These isoforms have
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unique, but overlapping, patterns of expression in a variety of tissues (Couse and
Korach, 1999a; Nilsson et al., 2001; Pettersson and Gustafsson, 2001). (From now on,
the use of the term “ERs” will refer to both ERα and ERβ, unless otherwise stated.)
Although their activities are functionally distinct, both isoforms share a similar
structure. ERs contain an N-terminal activation function (AF-1), a DNA-binding
domain (DBD),

and a C-terminal activation function (AF-2) which contains the

ligand-binding domain (LBD) (Enmark and Gustafsson, 1999) (Figure 1.1). The
expression of ERs in cells is a well-known prognostic indicator for some estrogendependent breast cancers (Jensen et al., 2001) and serves as the protein target for
SERMs (McDonnell et al., 2002; Sommer and Fuqua, 2001). While several nuclear
and non-nuclear mechanisms of ER-dependent transcription have been described
(Figure 1.2) [reviewed in (Barnes et al., 2004)], only the ligand-dependent nuclear
actions of ER are addressed in this work.

ER-dependent Transcriptional Regulation in the Nucleus: Direct DNA Binding
Upon hormone stimulation, ERs dissociate from nuclear chaperone proteins, dimerize,
and bind to DNA sequences known as estrogen response elements (EREs). Estrogendependent transcriptional regulation through the ERE pathway involves a variety of
cofactors that function with liganded ERs to modify histones, alter chromatin
structure, and recruit the RNA polymerase II (Pol II) transcriptional machinery (Kraus
and Wong, 2002). Many coactivators (i.e., stimulatory cofactors) bind directly to
agonist-activated AF-2 of ER through short α-helical "LXXLL" motifs called NR
boxes (Glass and Rosenfeld, 2000; Leo and Chen, 2000; Robyr et al., 2000). In
general, antagonists fail to induce the proper AF-2 conformation and thus block
receptor-coactivator interactions (Nichols et al., 1998).
following:

Coactivators include the

(1) histone-modifying enzyme (HME) complexes that contain
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Figure 1.1 Schematic of ERα and ERβ domains.
ERs share a conserved functional domain structure. This includes an amino-terminal
activation function 1 domain (AF-1), a DNA-binding domain (DBD), and an
activation function 2 domain (AF-2) that contains the ligand-binding pocket.
Sequence homology is represented as a percentage for each functional domain.
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Figure. 1.2 Estrogen-dependent signaling pathways.
Estrogen (E2) signaling pathways include: (1) the ligand-dependent binding of the
estrogen receptor (ER) directly to EREs (“Classical”), (2) the ligand-dependent
binding of ER to DNA-bound transcription factors (TF) (“Non-Classical”), and (3) the
activation of kinase cascades by membrane-associated ER (“Extra-Nuclear”). Figure
modified from (McDevitt et al., 2008).
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members of the steroid receptor coactivator (SRC) family of proteins as the receptorbinding subunit (Leo and Chen, 2000), (2) chromatin remodeling complexes such as
SWI/SNF (Kingston and Narlikar, 1999; Robyr et al., 2000), and (3) Mediator
complexes (e.g., TRAP and DRIP) which contain Med220/ TRAP220 as the primary
receptor-binding subunit (Malik and Roeder, 2000; Rachez and Freedman, 2001)
(Figure 1.3). HMEs include the histone acetyltransferases (HATs) p300/CBP and the
histone methyltransferase (HMT) CARM-1, which covalently modify histones to
change the structure and function of chromatin (Davie and Chadee, 1998; Narlikar et
al., 2002). Chromatin remodeling complexes alter local nucleosomal structure to
relieve chromatin-mediated transcriptional repression (Hebbar and Archer, 2003;
Kingston and Narlikar, 1999; Varga-Weisz, 2001). Mediator functions to stabilize the
formation of a stable Pol II-dependent transcription preinitiation complex (Malik and
Roeder, 2000; Rachez and Freedman, 2001). These coactivators are recruited by
steroid receptor proteins to promoter regions containing hormone-responsive elements
and ultimately facilitate transcriptional activation (Kinyamu and Archer, 2004).

ER-dependent Transcriptional Regulation: Tethering Pathway Overview
Cellular signaling by estrogens is not limited to ERE-dependent transcription. In fact,
multiple lines of evidence point to the interaction of ER with several transcription
factors via their recognition elements (e.g., NF-κB, Sp1, AP-1). Indeed, the direct
interaction of ER with NF-κB (Vandel et al., 1995) has been described with respect to
E2-mediated regulation of the interleukin-6 promoter (Ray et al., 1997; Stein and
Yang, 1995). Interactions with AP-1 have also been described (Teyssier et al., 2001;
Webb et al., 1995), as well as the E2-dependent regulation of genes harboring AP-1
binding elements (such as collagenase, human insulin growth factor 1, chicken
ovalbumin,

ovine

follicle-stimulating

6

hormone

β,

human

choline

A

B
Estrogen Response Element
(ERE)
AGGTCA NNN TGACCT

Figure 1.3 ER activation through an estrogen response element.
(A) After binding estrogen, ER dimerizes and binds to estrogen response elements
where it then recruits a cohort of factors such as histone modifying proteins, chromatin
remodeling proteins, and proteins associated with the basal transcription machinery
(B). The canonical estrogen response element is shown. N = any DNA base. Figure
modified from (Acevedo and Kraus, 2004).
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acetyltransferase gene) (Gaub et al., 1990; Miller and Miller, 1996; Paech et al., 1997;
Schmitt et al., 1995; Umayahara et al., 1994; Webb et al., 1995; Webb et al., 1999) or
those requiring AP-1 factors (DeNardo et al., 2005).
An interesting aspect of the ER/AP-1 pathway is that, under certain cell type
and promoter contexts, some classical ER antagonists can function as agonists (Harper
and Walpole, 1967; McDonnell et al., 2002; Paech et al., 1997; Webb et al., 1995;
Webb et al., 1999). Indeed, using an in vitro chromatin assembly and transcription
system, our lab has reconstituted ER-dependent activation through AP-1 binding
elements by both E2 and SERMs (Cheung et al., 2005) (Figure 1.4). Although the
molecular details of the ERE pathway are well characterized, our understanding of
ligand-dependent activation of the tethered pathway is quite limited, especially with
regard to the mechanisms of altered SERM pharmacology.

AP-1 Family of Transcription Factors
The AP-1 transcription factor is a dimeric complex composed of members of
the Fos (c-Fos, FosB, Fra1, and Fra2) and Jun (c-Jun, JunB, and JunD) bZIP protein
families (Foletta et al., 1998). Initially, AP-1 complexes were found to mediate gene
induction by the tumor promoting phorbol ester 12-0-tetradecanoylphorbol-13-acetate
(TPA). Because of this, the specific DNA sequence which AP-1 bound was called a
TRE (for TPA response element) (Figure 1.5). Fos and Jun, which were named after
the viral oncoproteins in the Finkel-Biskis-Jinkins osteosarcoma virus and avian
sarcoma virus 17, respectively (Vogt, 2002), were later identified as the proteins that
bound TREs. The stability and activity of AP-1 directly results from the composition
of its dimers [reviewed in (Eferl and Wagner, 2003; Shaulian and Karin, 2001;
Shaulian and Karin, 2002)].

For instance, Fos proteins do not form stable

homodimers, but rather, form heterodimers with Jun proteins that are more stable than
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Figure 1.4 Comparison of direct and tethered ER complexes.
(A) Using an in vitro chromatin assembly and transcription system the Kraus lab has
demonstrated ligand-dependent transcriptional activation of ERE and AP-1 driven
reporters (Cheung et al., 2005). ERα can activate transcription at both reporters in the
presence of 17β-estradiol (E2) but only the antiestrogens, Tamoxifen (OHT), ICI, and
Raloxifene can activate transcription through AP-1 sites. AdE4 = adenovirus E4
promoter products.
(B) This altered pharmacology whereby E2 agonists and antagonist can activate
transcription through AP-1 is one of the defining elements of ER activation through
AP-1 in vivo.
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A

10

Figure 1.4 (Continued)

B

11

Side view

End view

AP-1
dimers

Dimerization
domain

DNA
binding
domain
TGAGTCA

Figure 1.5 The AP-1 transcription factors. AP-1 proteins (members of the Jun and
Fos protein families) are basic-leucine zipper proteins. The leucine zipper domain
(shown in white with the leucine residues colored green) allows the dimerization of
Jun-Jun and Jun-Fos members. Once dimerized, their basic regions (shown in red)
interact with specific DNA sequences (shown in yellow) known as TPA-response
elements (TREs; TGAGTCA sequence). The model above only shows the bZIP
regions of c-Fos and c-Jun. The picture was generated with Pdb viewer using the
published crystal structure (Glover and Harrison, 1995).
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Jun:Jun homodimers (Angel and Karin, 1991). The AP-1 members that compose
these dimers can be quite different. Some AP-1 proteins, such as c-Fos, FosB, and cJun, contain potent activation domains which allow them to promote cell
transformation (Jochum et al., 2001). In contrast, Fra1 and Fra2 have weak activation
domains and weak transforming activity (Bergers et al., 1995; Foletta et al., 1994),
while JunB and JunD have no transforming ability (Vandel et al., 1995).

Regulation of AP-1 proteins
Before exploring ER-dependent activation through the AP-1 pathway, it is
important to have a basic understanding of AP-1 activation.

Induction of AP-1

activity can occur by two different mechanisms: (1) by increasing the transactivation
ability of the AP-1 factors and (2) increasing the overall level of the AP-1 factors.
Both of these mechanisms are modulated by MAPK cascades explained in more detail
below.

MAP kinase cascades
AP-1 proteins are regulated by MAP kinase cascades which convey a response
from various cell surface stimuli to intracellular targets by signal transduction
pathways.

Signal transduction occurs by a series of three kinases that form a

phosphorylation-relay [reviewed in (Davis, 2000; Hagemann and Blank, 2001;
Johnson and Lapadat, 2002; Vlahopoulos and Zoumpourlis, 2004)]. The first kinase,
known as a MAP kinase-kinase-kinase (MAPKKK) is activated by phosphorylation of
serine and threonine residues (Davis, 2000; Kyriakis and Avruch, 2001).

The

activated MAPKKK phosphorylates a MAPK-kinase (MAPKK) in a similar fashion,
which then becomes active and phosphorylates the final kinase, a MAP kinase
(MAPK). MAP kinases differ from their upstream enzyme activators in that their
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phosphorylation is on a Thr-x-Tyr motif, where x is any given amino acid (Davis,
2000; Kyriakis and Avruch, 2001) (Figure 1.6A). This phosphorylation enables the
MAP kinases to translocate to the nucleus and phosphorylate their target protein(s)
(Cavigelli et al., 1995). There are three subfamilies of MAP kinases which include the
extracellular signal-regulated kinases, ERKs; the c-Jun N-terminal kinases, JNKs; and
the p38s (Johnson and Lapadat, 2002).

AP-1 regulation by post-translational modification
Phosphorylation of c-Jun on serines 63 and 73 (Ser63/73) in its amino-terminal
region enhance its ability to activate transcription (Hibi et al., 1993; Pulverer et al.,
1991; Smeal et al., 1992). This activation is most likely due to the phosphorylationdependent recruitment of the transcriptional coactivator CBP (CREB binding protein)
to c-Jun (Bannister et al., 1995). c-Jun is phosphorylated by specific MAPK members,
JNKs, following cell stimulation by various conditions (e.g., TPA, UV treatment,
protein synthesis inhibitors) [reviewed in (Ip and Davis, 1998)]. Because c-Jun is
activated by phosphorylation, many genes which are regulated by AP-1 behave as
“immediate-early” genes.

These genes are rapidly induced upon cell stimulation

independently of de novo protein synthesis.
Three JNK proteins are known, JNK1, JNK2 and JNK3, with overlapping and
distinct functions. These kinases can all bind to a docking site in c-Jun known as the δ
(delta) domain (Dai et al., 1995) and phosphorylate Ser63/73 when activated (Hibi et
al., 1993) (Figure 1.6 B and C). JNK1 and JNK2 are more ubiquitously expressed
while JNK3 is mainly expressed in the brain (Mohit et al., 1995). Due to splice
variations, ten JNK isoforms exist (4 for JNK1, 4 for JNK2, 2 for JNK3) with JNK1
expressed predominantly as a 46 kD protein and JNK2 as a 54 kD protein (Derijard et
al., 1994; Kallunki et al., 1994; Mohit et al., 1995). Although JNK1 and JNK2 have
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Figure 1.6 The JNK MAP kinases: activation, recognition and modification.
(A) MAP kinases (like JNKs) are activated as the result of a phosphorylation relay
system. Blue arrows represent phosphorylation of serine and threonine residues, red
arrow represents phosphorylation of threonine and tyrosine residues.
(B) JNK substrates, like c-Jun and JIP-1, contain a JNK binding domain composed of
basic and hydrophobic amino acids (shown as red and green letters). Once bound,
JNK can phosphorylate proline-directed serines. Serines 63 and 73 in c-Jun (shown in
magenta) are well-known targets of JNK modification.
(C) The picture of JNK1 was generated with Pdb viewer using the published crystal
structure of JNK1 (Heo et al., 2004). SP600125 (structure shown in the white box), a
competitive ATP inhibitor of JNK MAP kinases, is bound in the ATP-binding pocket.
The JNK binding domain of JIP (sequence from B) is also shown bound to JNK1.
Red and green amino acids are the same as those illustrated in B.
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redundant functions, recent studies using JNK knockout mice have highlighted
specific roles for JNK1 and JNK2 [reviewed in (Sabapathy et al., 2004)]. JNK1 seems
to be the main kinase which phosphorylates c-Jun in response to cell stimulation
(Sabapathy et al., 2004) , while JNK2 is thought to mediate ubiquitin-mediated c-Jun
turnover in unstimulated cells (Fuchs et al., 1998; Sabapathy et al., 2004). Although
c-Jun can also be phosphorylated by other MAPK members (e.g., ERK1 and ERK2),
the phosphorylated residues are in the C-terminal region of the protein and are not
associated with transactivation, but rather, the inhibition of homodimers to bind DNA
(Chou et al., 1992; Minden et al., 1994).
c-Fos can also be regulated by phosphorylation. Its C-terminal region contains
a sequence similar to the phosphorylated sequence of c-Jun (Sutherland et al., 1992).
Threonine-232, the c-Fos equivalent of serine-73 in c-Jun, is located in this region and
is phosphorylated by the Fos-regulating kinase (FRK) but not by JNKs (Deng and
Karin, 1994). I have found that JNK1 can phosphorylate c-Fos in vitro when bound to
c-Jun. Although this may be the result of artificially altering JNK1 specificity, it also
demonstrates the role of c-Jun as a scaffold protein between JNK and Jun interacting
proteins, like c-Fos.

The mechanism of transcriptional activation through c-Fos

phosphorylation is still unclear. I have also conducted in vitro acetylation assays that
also indicate that both c-Fos and c-Jun are targets of acetylation by p300 (data not
shown) revealing the possibility of another post-translational modification that could
regulate AP-1 activity. To date, it is unknown if the modification state of c-Fos and cJun plays a role in the ability of ER to mediate transcription through AP-1.
Activation of MAP kinase cascades can also result in the upregulation of
transcription at the c-FOS and c-JUN genes [for review see (Karin, 1995)] increasing
the overall levels of AP-1 components. Both genes are poised for activation through
the MAP kinase-dependent phosphorylation of the transcription factors that
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constitutively occupy their promoters [e.g., Elk-1 at c-FOS (Treisman, 1992); c-Jun at
c-JUN (Rozek and Pfeifer, 1993)]. So, MAP kinase activation can not only affect AP1 activity by post-translational modification, but it can also indirectly affect AP-1
activity by altering the relative AP-1 abundance and composition, as well.

Molecular Crosstalk in the ER/AP-1 Pathway
Although ERs do not bind directly to TREs (Jakacka et al., 2001), they can be
recruited by protein-protein interactions with c-Jun and can convey E2 responsiveness
to genes lacking EREs. AP-1 activity can be induced by E2 treatment and reduced by
antiestrogens without an increase in c-Fos and c-Jun expression (Philips et al., 1993).
E2 can also inhibit AP-1 activity most likely by a mechanism involving ERβ and JNK
(Srivastava et al., 1999). How E2 effects AP-1-induced gene transcription has been
shown to depend on the ER isoform involved (Paech et al., 1997; Watanabe et al.,
1997; Webb et al., 1995). Although ERα plays a role in E2-activating effects through
AP-1, ERβ mediates the E2-inhibiting effects through AP-1 (Paech et al., 1997). The
AF-1 region of ERα and ERβ are quite different suggesting this domain may be
responsible for the differential regulation of ER-responsive genes (Couse et al., 1997).
These phenomena may be facilitated by the differential recruitment of AF-1
coactivators to TREs and their subsequent phosphorylation by JNK (Feng et al., 2001),
though, this still needs to be determined.
As noted above, ERs interact with the coactivators SRC-1 and CBP/p300. cJun and c-Fos also directly interact with SRC-1 and CBP/p300 and these
transcriptional activators regulate AP-1 dependent transcriptional outcomes (Bannister
et al., 1995; Lee et al., 1998). Because of this, it has been proposed that the mutual
inhibition between some nuclear receptors and AP-1 is due to competition for the
same coactivator (Kamei et al., 1996). It is also believed that certain coactivators may
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also facilitate the positive interference between ERα and AP-1 as deletion of ERα
helix 12 (Webb et al., 1999) or mutations in ERα AF-2 that prevent the binding of
p160 coactivators dramatically inhibits estrogen-mediated transcriptional activation
through AP-1 (Teyssier et al., 2001). The Kraus lab has used a biochemical approach,
involving an in vitro chromatin assembly and transcription system, to compare
estrogen signaling through the ER/AP-1 pathway to estrogen signaling through the
ER/ERE pathway. Interestingly, these studies have shown that even though a similar
set of transcriptional coactivators (e.g., SRCs, CBP/p300) are utilized by both
pathways, their interactions, activities, and requirements in the two pathways are
distinct (Cheung et al., 2005). Taken together, these results suggest that although the
ER-mediated activities at EREs and TREs may be similar, they do represent distinct
mechanisms of ER action. It has also been shown that estrogen treatment causes the
recruitment of c-Fos, as well as, ERα to endogenous promoters containing TRE sites
(Kininis et al., 2007). This illustrates that ER-mediated activities at TREs are not
limited to coactivator-dependent mechanisms, but may also affect the core AP-1
component. A more complete understanding of the proteins used by both pathways is
needed to fully comprehend the coactivator crosstalk between ER and AP-1.

Association of ER with AP-1
Although previous studies have shown that ERα directly interacts with c-Jun
(Qi et al., 2004; Teyssier et al., 2001; Webb et al., 1995), the nature of the interaction
(i.e., the protein domains involved) is unclear, as contradictory results have been
published.

For instance, in 1995 a group using GST-tagged ERα constructs

demonstrated an interaction between in vitro translated c-Jun and an amino-terminal
region (amino acids 1-185) of ERα, while the ligand binding domain of ERα could
not facilitate c-Jun binding (Webb et al., 1995). Later, in 2001, another group (using a
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similar in vitro binding assay) demonstrated an interaction between the hinge region of
ERα (specifically amino acids 259-302) and the carboxy-terminal region of c-Jun
(Teyssier et al., 2001).

They went on to further contradict the previous study by

showing the interaction of c-Jun with an ERα construct lacking the first 250 amino
acids. They also stated that the phosphorylation status of c-Jun was not a factor in
ERα binding. Finally, in 2004, it was shown that ERα interacts with the aminoterminal region of c-Jun and that this interaction was strongest when c-Jun was
phosphorylated on Ser63 and Ser73 (Qi et al., 2004). What can be drawn from these
contrasting studies is that ERα can directly interact with c-Jun and that this interaction
does not absolutely require the phosphorylation of c-Jun. ERα can also interact with
JunB and JunD but not members of the Fos family (c-Fos, FosB, Fra2, Fra1. The
protein domains that facilitate these interactions are still unclear.

Mouse model system for studying non-classical ERα action
The understanding that estrogen-dependent actions were mediated through ER
lead to the development of model systems designed to tease apart the molecular
actions of the receptor. In 1993, a ERα knock-out mouse was made by insertional
disruption of the ERα gene (Lubahn et al., 1993). This gene was not referred to as
ERα since ERβ was not discovered until 1996 (Kuiper et al., 1996; Mosselman et al.,
1996). Similar methods were used to generate the ERβ knock-out mouse in 1998
(Krege et al., 1998). These knock-out models have provided an invaluable resource
for determining the biological functions of ERα and ERβ [summarized in (Couse and
Korach, 1999a)] although they provide little to no information concerning the
differences between the different molecular mechanisms of ER action. In order to
provide a more useful tool for non-classical ER studies, Jakacka and colleagues
determined the specific amino acids in the DNA-binding domain of mouse ERα that
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facilitated ERE binding but did not affect AP-1 binding (Jakacka et al., 2001) (Figure
1.7A).

Indeed, the E207A/G208A mutant (“AA”) eliminated ERE binding and

activation of ERE-containing reporter genes while still able to activate a TREcontaining reporter and interact with c-Jun. This non-classical ER was introduced into
mouse by targeted insertion (“knock-in”) to distinguish between classical and nonclassical ERα actions in vivo (Jakacka et al., 2002).
The knock-in model provided several useful findings. First, while the ERα
heterozygous knock-out females (ERα+/-) were fertile (Dupont et al., 2000; Lubahn et
al., 1993), the heterozygous knock-in females were not. This phenotypic difference is
either the result of antagonism between the wild-type allele and the AA mutation, or
the net imbalance of contributions from the classical and non-classical pathways.
Whatever the mechanism, it underscores the importance of the non-classical pathway
in the development and function of the female reproductive system. Because the
heterozygous AA males had normal fertility (Jakacka et al., 2002), a cross with ERα
+/-

females produced hemizygous AA progeny (ERαAA/-) (Figure 1.7B). These mice

have been used successfully in at least three studies to date to identify a physiological
role for non-classical ERα signaling in uterus (O'Brien et al., 2006), bone (Syed et al.,
2005) and testes (Weiss et al., 2008). Future studies using the hemizygous AA mice
will most likely define the role of ERE-independent hormone signaling in other
tissues.

Genomic analyses: ChIP and bioinformatics
Recent scientific advancements, like the sequencing of the human genome and
the development of large-scale analytical techniques using microarray technology
(e.g., ChIP-chip), have facilitated the examination of ER-containing complexes on a
genomic scale. Indeed, several reports (9 to be exact) have described the genomic
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Figure 1.7 Mouse models for studying ER-dependent processes.
Although ERα and ERβ knock-out mice are invaluable tools in our search to
understand the role of the ER in mediating physiological responses, these models do
not discern between the different mechanistic pathways of ER-dependent actions.
(A) Jakacka and colleagues described a double mutation in the DNA binding domain
of ERα (E207A / G208A, shown in yellow) that abolished its ability to interact with
an ERE while retaining the ability to activate transcriptional responses through an AP1 reporter (Jakacka et al., 2001).
(B) Knock-in mice were made with this double alanine (“AA”) ERα to determine the
role of non-classical signaling in vivo (Jakacka et al., 2002). Since the knock-in
heterozygous females were infertile, the heterozygous males had to be crossed with
heterozygous knock-out females in order to produce mice expressing only the nonclassical ERα. A diagram of the crossing scheme is shown.
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localization of ERα using ChIP-based assays [ERα localization conclusions and
methods reviewed in (Kininis and Kraus, 2008)].

Bioinformatic analyses of the

sequences composing ERα bound regions indicated an enrichment in AP-1 motifs
providing genomic support for non-classical ERα complexes in vivo (Carroll et al.,
2006; Kininis et al., 2007). The determination of ERα/AP-1 complexes has also been
accomplished using an expression microarray approach (DeNardo et al., 2005). This
study identified E2-regulated genes that were affected by a blockade in the AP-1
pathway (accomplished by the inducible expression of a c-Jun dominant negative).
These genes, not surprisingly, were enriched for AP-1 sites demonstrating that even
expression microarrays can be used to predict ERα/AP-1 complexes in vivo.
Unfortunately, our understanding of non-classical E2 signaling from the
perspective of AP-1 is greatly lacking. Only two “genomic scale” data sets (c-Fos and
c-Jun) are available for AP-1 factors (Bruce et al., 2005a; Bruce et al., 2005b). The
data from these studies are not particularly useful with respect to ER signaling since
the ChIP-chip analysis was not conducted in the presence of hormone and the cell-line
used did not even express ER. Examination of AP-1 factors, in a manner similar to
that of ERα, is greatly needed to further the understanding of hormone-dependent
tethering through these proteins.

Remaining questions
Previous genomic studies (mentioned above) have demonstrated that AP-1
sites are associated with ERα binding. Knowing this only reminds us that nonclassical ERα complexes exist instead of furthering our understanding. What needs to
be determined, besides the cataloging of specific promoters containing ERα/AP-1
complexes (a feat which still needs to be accomplished), is the contribution of AP-1
(or other tethering components) to these tethered complexes. What are the AP-1
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members that mediate E2 signaling? For years it seems we have viewed the nonclassical ER pathway as a modified version of ERE-dependent signaling when, in fact,
it most likely represents an entirely different mode of E2 (and even SERM) signaling.
Future studies should focus on mapping all the AP-1 family members by ChIP using
estrogen-responsive models, instead of just relying on bioinformatic analyses to
determine possible AP-1 sequences, which may not represent functional AP-1 sites.
Understanding the hormone-dependent binding of AP-1 and its related factors, I
believe, will truly allow a greater understanding of the ERα/AP-1 pathway.
Besides the known interaction between ER and c-JUN (which remains illdefined), there may also be a physical interaction between ER and AP-1 coregulators
such as JNK. It is possible that JNK could associate with liganded ERs since a recent
study has shown that JNK1 directly interacts with another steroid receptor, the
glucocorticoid receptor (GR). This interaction occurs in a ligand-dependent manner
through a “delta-like” docking domain in GR (Bruna et al., 2003). Furthermore, E2
with ERβ can repress AP-1-dependent transcription by the inhibition of JNK activity
(Srivastava et al., 1999) suggesting a possible functional interaction between ER and
JNK. Further analysis of the molecular crosstalk between these two pathways will
help to elucidate the mechanisms of ER-dependent activities through AP-1.
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CHAPTER 2
Estrogen Regulation Through the Tethered Pathway is Mediated By
Multiple AP-1 and AP-1 Like Proteins*

*Dr. Nina Heldring contributed to this work by assisting with the proteomic
confirmations and performing the ChIP experiments.
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Summary
In this study, I set out to define the AP-1 components involved in mediating
the ERα/AP-1 pathway. I discovered various AP-1 family members were recruited to
an estrogen responsive TRE site, thereby expanding the view that other AP-1 factors,
besides just c-Jun, can mediate E2-dependent responses. I also found that “AP-1 like”
transcription factor family members (those belonging to the CREB and Maf protein
families) might also play a role in the recruitment of ER to E2-regulated promoter
regions. Finally, I identified several putative AP-1 coregulators that may mediate
transcriptional outcomes through TREs. Together, my results expand the limited
understanding of E2-regulated events mediated through TRE and TRE-like motifs and
provide new avenues for future research.

Introduction
Estrogen (E2) signaling can occur through at least two distinct pathways. The
first pathway is mediated by the direct binding of estrogen receptors (ERs) to
estrogen-response elements (EREs). The second pathway is mediated by the indirect
“tethering” of ER to DNA through protein-protein interactions with other transcription
factors like AP-1. Although it is known that ER can interact with c-Jun (an AP-1
member) at TPA-response elements (TREs) (discussed at length in Chapter 1), it
remains to be determined what other AP-1 members might facilitate the ERα tethering
pathway. It is also unclear if AP-1 specific coregulators play a role in mediating
hormone responses through TREs.

Although previous work has recapitulated

ERα/AP-1 dependent transcription in vitro (Cheung et al., 2005), the composition of
these TRE-dependent complexes has yet to be determined.
In this study, I determined the compostition of TRE-specific complexes in
order to have a better understanding of the factors involved in ERα/AP-1 complexes.
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Several techniques have recently been developed to identity protein-protein
interactions on a large scale. These studies, conducted in yeast, used the yeast 2hybrid method (Uetz and Hughes, 2000), an affinity chromatography approach
coupled with tandem mass spectrometry (MS/MS) (Gavin et al., 2002; Ho et al.,
2002), or a quantitative MS/MS approach (Ranish et al., 2003) to define proteinprotein interactions.

This latest approach identified the composition of in vitro

assembled promoter complexes using DNA templates to “fish out” promoter-binding
factors from yeast nuclear extract. It also utilized isotopically-labeled tags which
allowed the quantitative comparison of similarly purified complexes. I decided to use
this proteomic approach to identify components associated with TRE-dependent
complexes.

Results
Immobilized templates can capture enhancer specific complexes
In order to better understand how liganded ER activates transcriptional
responses through AP-1, I decided to take a step back and define the AP-1 components
that may play a role in the tethering of ERα. To this end, I developed an immobilized
template assay to isolate enhancer-specific complexes.

Three templates were

generated by PCR using a biotinylated forward primer. Each template had a unique
PstI site located upstream of the adenovirus E4 promoter. Five tandem TREs or 4
tandem EREs were inserted between the PstI site and the promoter region to isolate
AP-1 or ER complexes respectively (Figure 2.1A). A random sequence was inserted
to serve as a negative control. My plan was to immobilize the various DNA templates
to streptavidin coated beads through the 5’ biotin moiety, incubate the DNA with
HeLa nuclear extract to assemble enhancer-specific complexes, wash the DNA to
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remove nonspecific proteins, and elute the DNA-bound proteins by PstI digestion. I
would then detect the proteins by Western blotting.
I used the ERE template to isolate ER-containing complexes as a proof of
principle. The HeLa nuclear extract was supplemented with recombinant ERα, since
HeLa cells do not express either ERα or ERβ. Western analysis demonstrated that I
could purify ERα in an enhancer-specific manner using the immobilized templates
(Figure 2.1B). Moreover, when I added E2 during the assembly step, I noticed that I
could then purify two known ER coactivators, SRC1 and Med1 (also known as
Med220).

This demonstrated that I could isolate both proteins that directly and

indirectly bind enhancer DNA elements. Furthermore, using the TRE (but not the
ERE) template I found that I could purify two AP-1 factors, c-Fos and c-Jun. Taken
together, the immobilized template assay could isolate enhancer-specific complexes
from HeLa nuclear extract.

Unbiased proteomic screen identifies TRE-binding proteins
Since the TRE-containing promoter template mediates E2-dependent
transcription in vitro (Cheung et al., 2005), I hypothesized that some of the factors
facilitating this response may be associated with the TRE sequence even in the
absence of ERα. With the immobilized template assay working in my hands, I then
sought to identify the repertoire of factors that associated with the template in a TREdependent fashion. To this end I utilized an unbiased proteomic screen, previously
used to identify the protein components of affinity-purified RNA polymerase II preinitiation complex in yeast (Ranish et al., 2003). Briefly, this screen is based on the
use of isotopically labeled tags and tandem mass spectrometry to compare the relative
abundance of tryptic peptides between two isolated complexes. The power of this
method

is

that

it

can

distinguish
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components

of

affinity-

Figure 2.1 Immobilized DNA templates can isolate enhancer-specific complexes.
(A) A schematic of the immobilized DNA templates used to purify complexes from
HeLa nuclear extract is shown.
(B) Western blotting of the Pst1 eluted material demonstrates the specificity of AP-1
(Fos and Jun) recruitment to the TRE template (left) and the ligand-dependent
coactivator recruitment to the ERE template (right).
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purified complexes from a high background of co-purifying proteins eliminating the
need for stringent purification procedures.
To identify the components of TRE-associated complexes, I purified TRE
complexes from HeLa nuclear extract samples using the TRE immobilized template.
The non-TRE template was used as a control for factors associating with the TRE
template in an enhancer independent fashion. The control and TRE samples were
digested with trypsin and differentially labeled with either isotopically light tags (114
Daltons) or isotopically heavy tags (117 Daltons). Once labeled, the samples were
mixed together and subjected to further purification using strong cation exchange
(SCX) fractionation. This reduced the complexity of the sample allowing for a more
complete identification of the individual peptides by MS/MS (Figure 2.2). The SCX
fractions were analyzed by MS/MS by my collaborator, Jeff Ranish, at the Institute for
Systems Biology in Seattle, WA.
Using Protein Pilot software and the MS/MS spectral data, I determined both
the identity and relative abundance of the purified peptides. The relative abundance of
each peptide was expressed as the ratio of 117 signal to 114 signal as detected by
MS/MS. The Protein Pilot program normalizes the 117:114 ratios so that the average
ratio is equal to 1. This is based on the assumption that the majority of purified
proteins are “co-purified contaminants” and largely represent non-specific template
binding. Silver-staining of the isolated complexes revealed vastly complex mixtures
of proteins with no apparent difference in the banding pattern, justifying the
assumption for normalization (data not shown). Ratios greater than 1 represented an
enrichment of a peptide in the TRE template compared to the control template. The
peptide ratios from a given protein were averaged to determine the protein enrichment.
Peptides that mapped to more than one protein were not used in the protein enrichment
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Figure 2.2 Schematic of proteomic method to identify TRE-associated factors.
Control and TRE complexes were purified from HeLa nuclear extract using
immobilized templates.

Peptides from each sample were isotopically labeled,

combined for further processing, and analyzed by tandem mass spectrometry (MS) to
determine the identity and relative abundance of the proteins in each complex. B =
bead, E4 = adenoviral E4 promoter.
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calculation.

Using this method, I identified 1,063 proteins and their relative

abundance between the TRE and control templates.
This analysis revealed several transcription factors enriched in the TRE
purified sample (Figure 2.3A). Besides c-Fos and c-Jun, I identified three other AP-1
factors (Fra2, JunD, JunB) that bound the DNA template in a TRE-dependent manner.
The binding of these factors to the TRE template was confirmed by Western blotting
(Figure 2.4). Surprisingly, I also identified transcription factors belonging to the
CREB and MAF protein families, which classically bind cyclic AMP response
elements (CREs) and Maf recognition elements (MAREs), respectively. The proteins
comprising these families are similar to AP-1 proteins in that they bind DNA
sequences closely resembling TREs (Figure 2.3B). It is also known that AP-1 and
CREB members can dimerize and bind their respective DNA elements (Eferl and
Wagner, 2003). These findings not only implicate AP-1 proteins other than c-Fos and
c-Jun in the ER tethering pathway, but they also suggest that AP-1-like proteins (like
those belonging to CREB and Maf families) may also be playing a role in ER
tethering. This could be accomplished by members of these families binding to TREs
or by enabling the recruitment of ER to TRE-like enhancer sequences (like CREs or
MAREs).
My analysis also identified other TRE-specific components that may act as
regulators of TRE-dependent transcriptional outcomes (Figure 2.5). These factors
were not as enriched as the direct TRE-binding proteins which is consistent with the
idea that these proteins are indirectly recruited to DNA, possibly through the
transcription factors mentioned above. Although, I can not rule out a weak but direct
interaction between these potential regulators and the TRE-containing DNA template.
These factors included MAPKK7b (an upstream activator for the AP-1 MAP kinase,
JNK), SMARCA6 (an ATPase-containing protein associated with chromatin
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Figure 2.3 Proteomic approach identifies factors enriched in TRE-containing
template.
(A) The direct binding DNA factors enriched in the TRE-containing immobilized
template are shown. Fold and p-values determined by Protein Pilot software. Fold
equals the average 117:114 ratio for the given protein and represents the TRE
specificity (TRE:control ratio). * = p-value not determined due to the limited number
of peptides.
(B) The similarity between the DNA sequences classically bound by the protein
families mentioned in A are shown.
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Figure 2.4 Confirmation of AP-1 proteins enriched by proteomic approach.
The material purified using the TRE and control immobilized templates was analyzed
by immunoblotting. The AP-1 factors identified from the proteomic screen as
enriched for TRE-binding were confirmed, demonstrating not only their specificity but
also adding credibility to the proteomic results.
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Figure 2.5

Protein

Fold

p-value

MAPKK7b
Med8
TFIIA!
SMARCA6
RPB1
ZSCAN20
UBA5
ZIC2
TAF1
EP400

2.2
1.9
1.7
1.6
1.6
1.6
1.6
1.5
1.5
1.5

7.3 x 10-3
*
*
3.3 x 10-4
1.7 x 10-1
1.2 x 10-1
*
*
6.7 x 10-2
1.2 x 10-2

Related Process
AP-1 MAP kinase
Transcriptional coactivator
Transcription machinery
Chromatin remodeling
Transcription machinery
Unknown
Ubiquitin conjugation
Unknown
Transcription machinery
Histone acetylation

Coregulator proteins are also enriched in the TRE-containing

template.
Several factors were identified by our proteomic analysis as enriched in TRE-specific
complexes. The factors (minus the direct TRE-binding factors shown in Figure 3.4)
with at least 1.5 fold enrichment are shown. Fold and p-values determined by Protein
Pilot software.

Fold equals the average 117:114 ratio for the given protein and

represents the TRE specificity (TRE:control ratio). * = p-value not determined due to
the limited number of peptides.
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remodeling), and UBA5 (a ubiquitin-activating enzyme).

Taken together, my

approach identified several putative coregulators of TRE-associated complexes.
Future studies will establish the role of these factors not only in TRE-dependent
transcriptional outcomes, but determine if these factors play a role in mediating E2dependent transcriptional outcomes through AP-1 complexes.

Proteins identified by proteomic approach are modulated by E2 signaling in cells.
Armed with an understanding of the cohort of proteins able to bind TREs in
vitro, and knowing that these enhancers facilitate E2 dependent transcriptional
activation in the presence of ERα, I then wondered if I could detect the association of
these factors with ERα in cells using chromatin immunoprecipitation (ChIP). Because
the proteomic studies were done with nuclear extracts from HeLa cells, ChIP studies
were conducted in a HeLa cell-line that stably expressed ERα (HeLa-ER cells).
Candidate regions for ChIP analysis were chosen by overlaying ERα-bound regions
with regions containing AP-1 binding sequences (i.e., TREs or CREs). I defined
ERα-bound regions by ChIP-chip analysis using Nimblegen promoter arrays (ChIP
procedure, analysis, and arrays described in Chapter 3).

TRE and CRE motifs

(obtained from TRANSFAC) were mapped to genomic locations using MAST (same
method as described in Chapter 3). Candidate regions that also contained an ERE
motif (mapped by MAST) within the ERα-bound region were omitted to avoid
ambiguity concerning ERα recruitment.
ChIP-qPCR analysis of the candidate genes revealed the ligand-dependent
association of ERα with TRE and CRE-containing promoter regions (Figure 2.6 A and
B). The expression of these genes was transcriptionally regulated by E2 (unpublished
data from Dr. Nina Heldring) demonstrating that the recruitment of ERα correlated
with the transcriptional activation of these genes. Examination of AP-1 members by
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ChIP demonstrated the occupancy of these factors at endogenous TREs (Figure 2.6C).
The binding of JunD, Fra2, and c-Fos was enhanced by E2 treatment suggesting that
the presence of ERα at these regions either increases the affinity of AP-1 for DNA or
plays a role in the recruitment of these AP-1 factors. JunB occupancy was not E2
regulated demonstrating selectivity in the liganded ER modulation of AP-1. It is also
important to note that AP-1 factors can be found at CREs due to the high sequence
similarity between these motifs and the dimerization between members of these
families (Figure 2.6C, see c-Fos ChIP bottom panel). Interestingly, the CREB family
members ATF2 and CREB1 showed E2 dependent recruitment to CREs containing
ERα (Figure 2.6D).

Together, these examples demonstrate that E2 regulated

outcomes at TRE and TRE-like motifs may be mediated by more than just c-Fos and
c-Jun. Other factors, like Fra2, JunD, ATF2, and CREB1, may be more directly
responsible for conveying the hormone responsiveness at these promoters.

Discussion
This work describes the use of immobilized DNA templates coupled with a
quantitative proteomic approach to identify enhancer-specific complexes. Many of the
studies that have focused on understanding the mechanism ERα activation through
AP-1 sites have focused on the mapping and manipulation of ER-c-Jun interaction
surfaces, the role of various ligands, or the perturbation of ERα-coativator
associations (Cheung et al., 2005; Jakacka et al., 2001; Qi et al., 2004; Teyssier et al.,
2001; Webb et al., 1995; Webb et al., 1999). In this study, I attempted to identify the
repertoire of AP-1-associated factors that would be present on a known E2-responsive
TRE. I wanted to understand what ERα would “see” when it viewed an assembled
AP-1 complex.
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Using an immobilized template to isolate TRE-complexes, I found that several
AP-1 members were able to bind the AP-1 consensus (Figure 2.3). This demonstrates
how complex the AP-1 composition can be, further complicating our understanding of
tethered ERα complexes.

Interestingly, I did identify several AP-1-like proteins

belonging to the CREB and Maf transcription factor families. The presence of these
other factors suggests at least two conclusions. First, a canonical TRE can allow the
binding of other AP-1-like transcription factors in vitro. Although overlap between
TRE- and CRE-binding proteins has been demonstrated before [reviewed in (Eferl and
Wagner, 2003)], it reminds us that “TRE”, “CRE”, and “MARE” sequences, found in
vivo, are not limited to the just the protein families to which they immediately refer.
Indeed, ChIP analysis of c-Fos localization demonstrated the presence of this AP-1
protein at a CRE-containing promoter (Figure 2.6C).

This also argues for the

confirmation of specific AP-1 binding factors when bioinformatic approaches are used
to explain ERα recruitment or hormone responsiveness, since the motif, by itself, is
mechanistically ambiguous.

Secondly, the association of these AP-1-like factors

opens the door to other “tethering” proteins besides c-Jun. Indeed, work by Sabbah et
al. nearly a decade ago demonstrated the interaction of ERα with ATF2 (Sabbah et al.,
1999), yet little more is known about how this interaction mediates ERα tethering in
cells.

More recent work by the Katzenellenbogen lab reported evidence for an

interaction between ERα and CREB1 (Lazennec et al., 2001). Although this weak
interaction was most likely mediated by an indirect association, it underscores the idea
that factors other than c-Fos/c-Jun dimers are associated with tethered ERα
complexes.
I examined tethered ERα complexes in vivo to determine if the TRE-bound
factors from the proteomic study could be linked to E2-regulated complexes in cells.
To this end, I examined promoters in HeLa-ERα cells that had the following
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characteristics: (1) they displayed E2-dependent transcriptional activity, (2) liganddependent binding of ERα, (3) did not contain an ERE in the ERα-associated region,
and (4) contained an AP-1-like element (TRE or CRE) under the ERα-associated
region. The presence of several AP-1 factors was confirmed at these genes (Figure
2.6). It is interesting to note in these examples that E2 treatment causes the increase in
AP-1 factors and not simply the recruitment of ERα. Indeed, previous work from our
lab has shown the E2-dependent recruitment of c-Fos to the TRE-containing
UGT2B15 promoter (Kininis et al., 2007). A model that defines AP-1 proteins as
DNA-bound transcription factors that act as a “landing pad” for ERα does not seem to
fit the description seen in vivo. Perhaps these tethered complexes are formed in
solution in the nucleoplasm before they actually associate with the DNA. An alternate
model would be that AP-1 proteins are loosely associated with their DNA elements
and liganded ERα stabilizes these AP-1 factors on DNA. ER may stabilize some AP1 members (c-Fos, JunD) but not others (JunB) (Figure 2.6C).
The presence of ATF2 and CREB1 at a CRE was also confirmed by ChIP
(Figure 2.6D). As was the case for TRE, the factor recruitment was ligand-dependent.
To my knowledge this was the first description of the binding of ERα to a confirmed
CRE. Even if this interaction is indirect (as the evidence mentioned above suggests),
it still demonstrates that ERα can associate with a wide variety of AP-1-like proteins
in cells. Future work, using reporter assays or in vitro transcription systems, will need
to be conducted to determine the role of each tethering factor in E2-mediated
transcriptional activation.
My analysis also identified several putative AP-1 coregulators (Figure 2.5).
Although I did not focus on these factors due to the lack of available reagents, future
studies should determine if they are indeed bona fide coregulators of AP-1
transcription. It is interesting that four of the factors are associated with the basal
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Figure 2.6 Identification of tethered ERa complexes in HeLa-ER cells.
(A) A schematic of the promoter region for two TRE and two CRE genes is shown.
The arrows represent the location of the primer sequences used for PCR (below).
(B) Quantitative PCR of ERα ChIP material demonstrated the hormone-induced
occupancy of ERα at these regions.
(C, D) ChIP material for AP-1 (C) and CREB (D) family members are also shown for
the same genes. TSS = transcription start site, U = untreated, E = E2-treated. Red line
represents the average signal from “no antibody” immunoprecipitations.
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Figure 2.6 (Continued)
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Figure 2.6 (Continued)
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transcription machinery. An interaction between TBP (a component of TFIID) and the
bZIP domains of c-Fos and c-Jun has already been reported adding validity to the
proteomic enrichment for the TFIID component TAF1 (i.e., TAF250) (Ransone et al.,
1993).

Moreover, I identified UBA5, an E1 activating enzyme in the ubiquitin

conjugation pathway.

Previous work reported another enzyme in the ubiquitin

conjugation pathway, Ubc9, as an AP-1interacting protein suggesting that it plays a
functional role in the association between c-Jun and the glucocorticoid receptor
(Gottlicher et al., 1996). Other putative coregulators (like Med8, SMARCA6, and
EP400) may also play a role in mediating E2-dependent outcomes, similar to the
coregulators, SRC-1 (Cheung et al., 2005; DeNardo et al., 2005) and p300 (Cheung et
al., 2005; DeNardo et al., 2005; Kamei et al., 1996).
Finally, this study determined four new genes regulated, I believe, through
tethered ERα complexes. Further testing with more candidate promoters may lead to
the identification of more E2-regulated, ERE-independent genes.
Although initially I wanted to extend the proteomic analysis to include the
identification of ERα-containing TRE complexes, the efficiency of ERα-binding to
the TRE-containing template was not sufficient enough to allow the identification of
ER-dependent factors. Future modifications of the methodology described in this
work may enable the elucidation of these factors and an even greater understanding of
the mechanisms involved in ERα/AP-1 complex formation. Additionally, I hope to
determine the genomic localization of AP-1 components before and after E2 treatment
using ChIP-chip. It would be interesting to see if the E2-regulated AP-1 occupancy,
described for selected genes in this work, represents a global theme for ER-associated
AP-1 complexes.
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Materials and Methods

Nuclear extract preparation.

Nuclear extracts were prepared as described

previously (Dignam et al., 1983; Kraus and Kadonaga, 1998). Briefly, HeLa S3 cells
were maintained in MEM Eagle medium (Sigma M0518) pH 7.4 and supplemented
with 5% calf serum, NaHCO3, Penstrep, and MEM non-essential amino acids (Sigma
M7145). Cells were grown in suspension up to 8L and collected when the culture
reached a density of 0.5-1.0 x 106 cells per mL.

Cells were harvested by

centrifugation (J6-B rotor, 10 minutes at 3K rpm) and resuspended in cold PBS. The
cells were collected (GSA rotor, 10 minutes at 3K rpm), washed a second time with
cold PBS, and collected by GSA centrifugation. Cells were resuspended in 5 cell
pellet volumes of hypotonic buffer (20mM Hepes pH 7.9, 10mM KCl, 1.5mM MgCl2,
2mM DTT, 1mM Benzamidine, 2ug/mL Aprotonin, 2ug/mL Leupeptin, 0.2ug/mL
Pepstatin, 0.2mM PMSF) and incubated on ice for 15 minutes. Cells were then
pelleted using an IEC Clinical Centrifuge (10 minutes at setting 5), resuspended with 2
cell pellet volumes of hypotonic buffer, and dounced 15 times using a tight glass
pestle. The intact nuclei were collected after the cytoplasmic lysate was removed by
centrifugation (clinical centrifuge, 15 minutes at setting 6). Nuclei were resuspended
in 0.5 nuclei volumes of hypotonic buffer plus 20% glycerol. While stirring, 0.4
nuclei volumes of hypertonic buffer (20mM Hepes pH 7.9, 1M KCl, 1mM
Benzamidine, 2ug/mL Aprotonin, 2ug/mL Leupeptin, 0.2ug/mL Pepstatin, 0.2mM
PMSF) were added and the extraction proceeded for 45 minutes. The extracted nuclei
and lipid fraction were removed after centrifugation (SS34 rotor, 30 minutes at 16K
rpm) and the remaining HeLa nuclear extract (HNE) was dialyzed for 4hrs in dialysis
buffer (20mM Hepes pH 7.9, 100mM KCl, 0.1mM EDTA, 20% glycerol, 1mM DTT,
1mM Benzamidine). After dialysis, precipitates were pelleted by centrifugation (SS34

57

rotor, 20 minutes at 15K rpm) and the extract was aliquoted and stored at -80C. The
protein concentration was determined by Bradford assay.

Plasmids.

The templates used are derived from pIE0-E4 [described previously

(Cheung et al., 2005)]. TREx5 is the pIE0-E4 plasmid with an insertion of 5 tandem
TPA-response elements (TREs) upstream of the E4 promoter sequence. The unique
PstI site in both plasmids was moved so it was in the same location relative to the
transcription start site (TSS). Sequences for the modified plasmids are available upon
request.

Immobilized pull-down assay. Templates used for pull-down assays were generated
from the plasmids described above by PCR using a biotinylated forward primer (5’GATTGGTTCGCTGACCATTTCCGG-3’) located ~460 bases upstream of the TSS
and a reverse primer (5’-CAGCCTAACAGTCAGCCTTACCAG-3’) located ~85
downstream of the TSS. For each pull-down, approximately 360ng of amplified
template was incubated with 5ul of Dynabeads M-280 Streptavidin beads (10ug/ul) in
binding buffer (10mM Tris pH 7.5, 1mM EDTA, 1M NaCl, 0.003% IGEPAL) for 15
minutes at room temperature. (Since these beads are paramagnetic, all washes were
carried out by sequestering the beads to the side of the tube using a magnet, removing
the buffer, and then resuspending the beads in new buffer.) The DNA-bound beads
were rinsed with binding buffer and then resuspended in blocking buffer (20mM
Hepes pH 7.6, 100mM KOAc, 5mM MgOAc, 1mM EDTA, 3.5% glycerol, 60mg/ml
casein (Sigma C5890), 5mg/ml polyvinylpyrrolidone (USB 20611), 2.5mM DTT) for
30 minutes at room temperature. The blocked beads were then washed 3 times with
blocking buffer that lacked casein and polyvinylpyrrolidone and resuspended to their
original concentration (10ug/ul) in HNE binding buffer (20mM Hepes pH 7.9, 100mM
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KCl, 6mM MgCl2, 0.2mM EDTA). The beads were then incubated with 385ug of
HeLa nuclear extract diluted 1:1 with HNE binding buffer. Protein complexes were
allowed to form on the DNA templates for 1 hr at room temperature before the beads
were washed with HNE binding buffer and resuspended in PstI buffer (50mM Tris pH
7.9, 100mM NaCl, 10mM MgCl2) with 60 units PstI (Roche 10798991001). After 30
minutes at 37C, the beads were pelleted and the released DNA-bound proteins were
collected and analyzed by SDS-PAGE / Immunoblotting. For proteomic studies using
tandem mass spectrometry (MS/MS), the pull-down assay was scaled up 300 times to
provide enough eluted material for further processing. Only 680 units of PstI was
used (~11x) in the final elution so as not to interfere with subsequent protein
identifications by MS/MS.

Peptide preparation/Isotope labeling. The DNA-bound proteins, eluted from the
immobilized template assay, were concentrated to 70ul using Microcon spin columns
and SDS was added to 0.3%. The samples were boiled for 5 minutes to dissociate
DNA-protein interactions, cooled to room temperature, and reduced with 10mM
TCEP. The spin columns were rinsed with 300ul of 7.2M urea (made fresh) and this
mixture was added to the reduced proteins. After a 45 minute incubation at room
temperature, cysteine residues were blocked using 8mM MMTS for 10 minutes.
Samples were examined by SDS-PAGE/ silver staining and the protein concentrations
were calculated using dilution standards of HeLa nuclear extract. Approximately
800ug of each sample was diluted with TE (10mM Tris pH 8.3, 1mM EDTA) to
reduce the urea concentration to <0.9M and the SDS concentration to <0.01%.
Samples were then digested with 40ug of Trypsin and 8ug of Endoprotease LysC
overnight at 37C. After 1:1 dilution with Buffer A (5mM KH2PO4 pH 2.7, 25%
Acetonitrile), each sample was individually loaded onto a PolySULFOETHYL A
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(PolyLC, 202SE0503) HPLC column, washed with Buffer A, and eluted with Buffer
B (5mM KH2PO4 pH 6.0, 25% Acetonitrile, 0.5M TEAB). The eluates were dried,
resuspended in water and loaded onto a reverse phase C18 columns [Nest Group,
218SPE1000]. The columns were washed with 2% Acetonitrile, 0.1%TFA and eluted
with 80% Acetonitrile, 0.1%TFA. After the peptide samples were dried, 600ug (75%)
were labeled with either iTRAQ-114 or iTRAQ-117 (Applied Biosystems) according
to the manufacturer’s specifications. Isotopically labeled samples were combined and
the excess ethanol from labeling was removed by evaporation. The peptide mixture
was diluted 20 fold with Buffer A, loaded onto the PolySULFOETHYLA A column,
and fractionated by running the following gradient at 0.2 mL/min: 0-15% Buffer C
(5mM KH2PO4 pH 2.7, 25% Acetonitrile, 600mM KCl) for 30 min, 15-60% Buffer C
for 20 min, and 60-100% Buffer C for 15 min. I collected 32 fractions of 0.4 ml.
Each fraction was dried under reduced pressure and desalted using reverse phase C18
columns as described above.

Protein identification. Peptide fractions were resuspended in 2% acetonitrile, 0.1%
TFA. Approximately 40% of the sample was loaded onto an HPLC C-18 column
using an Agilent 1100 Binary pump in a split-flow configuration coupled to a LC
Packings Famos autosampler.

Peptides were resolved by running the following

acetonitrile gradient at 0.3mL/min: 2-10% for 5 min, 10-25% for 75 min, 25-35% for
15 min, and 35-80% for 5 min. Masses were detected using a QSTAR Pulsar i with
0.75s scan time for each MS read followed by 3 MS/MS reads using 2s scan time.
Only the most intense ions for charge states 2-4 were analyzed. Data files from the
individual fraction runs were collectively analyzed using Protein Pilot software.
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CHAPTER 3
Estrogen Regulates the JNK1 Genomic Localization Program to
Control Gene Expression and Cell Growth*

*Dr. Nina Heldring, Dr. Matt Gamble, and Adam Diehl contributed to this work
by assisting with the expression, ChIP-chip, and bioinformatic analysis,
respectively.
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Summary
Steroid hormone and MAPK signaling pathways functionally intersect, but the
molecular mechanisms of this crosstalk are unclear. Here I demonstrate an extensive
and unexpected convergence of the estrogen and JNK1 signaling pathways at the
genomic level in breast cancer cells. Estrogen signaling promotes a nearly complete
redistribution of JNK1 to estrogen receptor alpha (ERα)-bound promoters, primarily
through an ERα tethering pathway. JNK1 functions as a transcriptional coregulator of
ERα at many of these promoters in a manner dependent on its kinase activity. The
convergence of ERα and JNK1 at target gene promoters regulates estrogen-dependent
gene expression outcomes, as well as downstream estrogen-dependent cell growth
responses. Analysis of existing gene expression profiles from breast cancer biopsies
suggests a role for functional interplay between ERα and JNK1 in the progression and
clinical outcome of breast cancers.

Introduction
Diverse signaling pathways regulate a wide variety of cellular processes,
including global transcription programs, in normal and disease states. For example,
steroid hormones, such as estrogens, act through nuclear receptors to directly regulate
the expression of a defined set of target genes (Acevedo and Kraus, 2004; Kininis and
Kraus, 2008). In contrast, growth factors act through cytoplasmic membrane receptors
to stimulate intracellular signaling pathways, including mitogen activated protein
kinase (MAPK) cascades, that indirectly regulate gene expression through a variety of
target transcription factors (Turjanski et al., 2007). Although functional crosstalk
between steroid hormone and growth factor/MAPK signaling pathways was
demonstrated nearly two decades ago in models of steroid hormone-dependent cancer
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(Lange, 2004; Smith, 1998), our understanding of how these pathways converge at the
genomic level to regulate gene expression remains rudimentary.
To explore the convergence of these signaling pathways at target gene
promoters, I considered the possibility that Jun N-terminal kinase (JNK1), a MAPK
whose expression is upregulated in breast cancers (Figure 3.1), might function as a
coregulator of estrogen receptor alpha (ERα) at the promoters of estrogen-regulated
genes. Although the traditional view has been that MAPK-mediated phosphorylation
events (e.g., phosphorylation of transcription factors) do not occur at the genes that
they ultimately regulate, the terminal kinases of various signaling pathways are found
in the nucleus under activating conditions (Edmunds and Mahadevan, 2004; Turjanski
et al., 2007). In addition, genomic analyses in yeast (Pascual-Ahuir et al., 2006;
Pokholok et al., 2006) and gene specific analyses in cultured mammalian cells
(Edmunds and Mahadevan, 2004) have shown that some signaling kinases bind to the
promoters of genes whose expression they regulate. The aim of this study is to
characterize the genomic relationship between ERα and JNK1 in regard to their
genomic occupancy and transcriptional outcomes.

Results
JNK1 is recruited to genomic regions after estrogen treatment.
In order to determine if JNK could be modulated by estrogen (E2) in vivo, I
performed chromatin immunoprecipitation (ChIP) in MCF-7 cells treated with and
without E2 using antibodies for JNK1. I examined the JNK1 occupancy at several
genomic regions previously reported by ChIP to bind the ERα (Kininis et al., 2007).
Since it was already known that E2 could modulate protein-DNA interactions at these
regions, they seemed to be the best candidates for JNK1 ChIP. Indeed, I could detect
the presence of JNK1 by ChIP-qPCR at these loci (Figure 3.2A). Interestingly, I noted
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Figure 3.1 JNK1 expression is elevated in breast carcinomas.
The relative expression of MAPK8 (i.e., JNK1) from 4 normal breast stroma samples
and 51 breast tumor samples is shown. The data were obtained from a larger gene
expression analysis (Finak et al., 2008) through the Oncomine database (Rhodes et al.,
2004). The Oncomine-reported p-value was <3.0 x 10-4. The values were normalized
to an average expression level of 1 for the normal breast samples. Red lines represent
the average signal in each category.
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that JNK1 occupancy was induced by E2 treatment. The hormone-dependent binding
of ERα was also demonstrated for these regions, confirming the previous report
(Figure 3.2B). This novel JNK1 result was quite amazing since it implies that the
MAP kinase might be an estrogen-dependent cofactor in DNA-bound complexes.

Estrogen treatment does not affect global JNK1 localization.
It is known that mitogen activated protein kinases (MAPKs), like JNK1, are
regulated by the dual phosphoryation of their Thr-Pro-Tyr motif by upstream MAPK
kinases, and that this modification results in the translocation of the MAPK into the
nucleus and the activation of its enzymatic activity [for a review, see (Davis, 2000)].
Because glucocorticoids and other steroid hormones have been shown to alter the
enzymatic activity and cellular distribution of JNK (Bruna et al., 2003), I wondered if
E2 treatment altered the localization or activation status of JNK1 in this system.
To this end, cytoplasmic and nuclear extracts were prepared from MCF-7 cells
with and without E2 treatment. Western blotting showed that the nuclear retention of
ERα was increased upon hormone treatment demonstrating the effectiveness of
estrogen signaling, while GAPDH served as a cytoplasmic control illustrating proper
fractionation. Blotting for JNK1 revealed that although it was present in both the
cytoplasmic and nuclear extracts, only the phosphorylated form of JNK1 was detected
in the nuclear extract (Figure 3.3A), consistent with previous findings (Gupta et al.,
1995). The constitutive JNK1 phosphorylation may be the result of HER-2 dependent
MAP kinase hyperactivation [described for ERK (Keshamouni et al., 2002; Kurokawa
et al., 2000)] or related to the elevated kinase activity associated with breast cancer
cell-lines [e.g., AKT (Lin et al., 2005)]. Surprisingly, E2 treatment did not alter the
localization of JNK1 or the fraction of activated (phosphorylated) protein. Analysis of
MCF-7 cells by immunofluorescence also demonstrated similar levels of JNK1 in the
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Figure 3.2 ChIP analysis of JNK1 at ERα-occupied regions.
ChIP-qPCR results demonstrating JNK1 (A) and ERα occupancy (B) at promoters in
MCF-7 cells treated with ethanol (U) or E2 (E). Each bar = mean + SEM, n ≥ 3.
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cytoplasmic and nuclear compartments (Figure 3.3B).
Although the antibodies used for ChIP analysis were not phosphorylation
specific, I believe that the JNK1 complexes identified contain the phosphorylated form
of the protein since this is the predominant JNK form in the nucleus. Taken together, I
conclude that E2 treatment alters the occupancy of activated JNK1 on DNA without
altering the overall nuclear pool of JNK1.

ChIP-chip identifies global patterns of E2-dependent JNK1 occupancy at
promoter regions.
To obtain a broader understanding of our JNK1 ChIP results I turned to DNA
microarrays that allow a more global analysis of ChIP material rather than a gene by
gene approach. I used commercially available arrays from Nimblegen that contained
approximately 19,000 promoter regions tiled from -2200 to +500 base pairs (bp)
relative to each transcription start site. Three biologically independent ChIP samples
(representing two different JNK1 antibodies) were hybridized to the arrays and
analyzed using strict peak finding criteria. The comparison of JNK1 occupancy before
and after E2 treatment revealed 801 promoters that contained significantly higher
levels of JNK1 occupancy after E2 treatment (“JNK1-recruited”) and 235 promoters
that demonstrated a significant loss of JNK1 occupancy after E2 treatment (“JNK1released”) (Figure 3.4A). Averaging of peak centered ChIP-chip data across these
classes illustrates the distinct patterns JNK1 promoter localization in response to E2
(Figure 3.4B).

Gene-specific ChIP-qPCR revealed both a high confirmation rate

(~93%) for JNK1 peaks on the array (Figure 3.5) and local features consistent with our
ChIP-chip tiling (Figure 3.6). I also noted that the JNK1 peaks were found throughout
the promoter regions with no apparent preference for the TSS, as is the case for other
DNA-associated factors (i.e., PARP-1) (Krishnakumar et al., 2008).
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Figure 3.3 Estrogen treatment does not affect global JNK1 localization.
(A) MCF-7 cells were treated with ethanol (U) or E2 (E) for 45 min., and fractionated
into cytoplasmic (Cyto) and nuclear (Nuc) extracts. The extracts were analyzed by
Western blotting to determine the subcellular localization of JNK1. Arrows indicate
the slower migration of phosphorylated JNK1.

ERα and GAPDH were used as

fractionation controls.
(B) MCF-7 cells treated as above were subjected to immunostaining with a JNK1
antibody, and visualized by confocal microscopy. A single nucleus in each panel is
denoted by a dotted circle. This data is consistent with my subcellular fractionation
analysis, which shows no gross change in JNK1 localization upon estrogen treatment.
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Figure 3.4 ChIP-chip reveals JNK1 localization patterns at promoter regions.
(A) A heatmap showing JNK1 ChIP-chip signals from MCF-7 cells across target
promoters before (U) and after (E) a 45 min. treatment with E2 is shown. The
promoters were arrayed from -2200 to +500 bp relative to each TSS (x-axis).
Analysis of JNK1 occupancy revealed promoters with more JNK1 after E2 treatment
(“Recruited”), less JNK1 after E2 treatment (“Released”), no change in JNK1 after E2
treatment (“Constitutive”), and no JNK1 (“Absent”). The genes in each category (yaxis) are ordered from those with the 5'-most JNK1 peak to those with the 3'-most
JNK1 peak. Only 2% of the 17,297 "Absent" genes are represented.
(B) The genes in each category were aligned to the maximal JNK1 ChIP-chip signal.
The peak-centered data was then averaged to demonstrate the overall pattern for each
category shown in (A).
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Figure 3.5 ChIP-qPCR confirms JNK1 ChIP-chip categories.
(A, B) ChIP-qPCR confirmation of "JNK1-recruited" (A) and "JNK1-released" (B)
promoters in MCF-7 cells treated with ethanol (U) or E2 (E). Greater than 93%
(28/30) of the regions tested by ChIP-qPCR confirmed the ChIP-chip results. CHPT1
and UGT2B15 are false negatives due to the limited number of probes present in their
respective peak regions on the ChIP-chip array (due to repeat masking). ChIP-qPCR
and visual inspection of their ChIP-chip tiling profiles confirms that they are true
"JNK1-recruited genes." Each bar = mean + SEM, n ≥ 3. The red line in each graph
represents background JNK1 signal.
(C)

ChIP-qPCR to determine JNK1 occupancy at bound (Significant; Sig) and

unbound (Background; Bkg) regions as defined by the ChIP-chip experiments
demonstrates the validity of the peak calls. Red bars represent the average signal in
each category.
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Figure 3.6 ChIP-qPCR analysis is consistent with ChIP-chip tiling features.
ChIP-chip tiling (left) and ChIP-qPCR (right) analyses of JNK1 at three promoter
regions from MCF-7 cells treated with ethanol (U) or E2 (E) is shown. The average
JNK1 ChIP-qPCR signals from peak (gray box) and non-peak (bracket) regions
defined by the ChIP-chip tiling are consistent with the array profiles. For the ChIPqPCR, each bar = mean + SEM, n ≥ 2.
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These results confirmed the previous finding that JNK1 required E2 treatment
for occupancy at some loci, but also revealed that E2 treatment could contribute to the
removal of JNK1 from other loci.

Interestingly, a relatively small number of

promoters (29 genes) contained similar levels of JNK1 before and after hormone
treatment demonstrating that the majority of identified JNK1 complexes are regulated
by E2.

JNK1-bound promoters are enriched for specific cellular functions.
I next wanted to determine if the JNK1-recruited and JNK1-released genes
were enriched for particular cellular functions. Using Genecodis (Carmona-Saez et
al., 2007), I determined that both the “JNK1 recruited” and “JNK1 released” gene sets
showed enrichment for specific ontological categories (Table 3.1). For example, the
“JNK1 recruited” gene set is enriched in genes encoding components of G-proteincoupled receptor signaling pathways and enzymes that metabolize steroid hormones.
The proteins encoded by both of these ontological categories of genes would be
expected to affect estrogen signaling responses, either by modulating growth factor
signaling (Smith, 1998) or by metabolizing estrogens into less active or alternately
active forms (Zhu and Conney, 1998). The “JNK1 released” gene set is enriched in
genes encoding several mRNA-binding proteins associated with nuclear splicing.
These include SF3B5 [a component of the splicesome complex (Zhou et al., 2002)],
DHX38 [an RNA helicase (Schwer and Guthrie, 1991)], and RBM8A [a component of
the exon junction core complex (Ballut et al., 2005)]. These genes reinforce the recent
link between JNK signaling and the regulation of alternative splicing (Pelisch et al.,
2005).
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Table 3.1 Gene ontology of JNK1 bound promoters.
Ontologya

p-valueb

• GPCR signaling pathway

9.3 x10-4

• Glucuronosyltransferase activity

2.5 x10-5

• Metabolism of androgens and estrogens

6.0 x10-6

"JNK1-released"
promoters
(235 genes)

• Nuclear mRNA splicing via the
spliceosome

1.3 x10-5

Five random gene setsc

• None

Gene set
"JNK1-recruited"
promoters
(801 genes)

a

<0.001

Ontologies were obtained using Genecodis for the JNK1-recruited and JNK1-

released genes. The entire gene list represented on the ChIP-chip array was used as
the background reference. Ontological assignments representing less than 5 genes
were not considered.

b

p-values were determined by Genecodis using Chi-square tests. Randomized gene

lists (of equal size to each gene set analyzed) were generated from the genes present
on the ChIP-chip array to determine a significance threshold and demonstrate the
specificity of ontology assignments.

c

Five random gene sets were generated using the programming language R from the

total number of genes present on the ChIP-chip array. No gene ontologies were
enriched (i.e., all p-values were >0.001) in the random lists using the criteria described
above.
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Recruited JNK1 peaks correlate with ERα occupancy.
Given the estrogen-dependent alterations in the JNK1 genomic localization
program, I tested the possibility that the JNK1 peaks might correspond to sites of ERα
binding.

My initial investigation of JNK1 localization already demonstrated that

JNK1 was recruited to regions where ERα was also recruited. To explore this more
globally, I performed ERα ChIP-chip using the same array platform that I used for
JNK1. These results show a strong correlation between JNK1 and ERα binding sites
in the promoter regions, with about 85% of the JNK1 recruited peaks overlapping an
ERα peak (Figure 3.7). ChIP-qPCR assays confirmed that the JNK1 recruited peaks
correlated with an E2-induced occupancy of ERα at promoter (Figure 3.8A) and distal
enhancer regions (Figure 3.8C). To my surprise, the JNK1 released peaks were not
associated with ERα occupancy (Figure 3.8B).

These patterns of E2-dependent

regulation of JNK1 and ERα binding are clearly evident for specific target promoters
where the overlay of JNK1 and ERα peak regions using ChIP-chip tiling illustrates the
specificity of their association (Figure 3.9). This suggests that JNK1 and ERα are corecruited at JNK1 recruited regions. JNK1 seems to be modulated by a different
mechanism at JNK1-released regions.

Nuclear E2 signaling is required for JNK1 recruitment.
The induced binding of JNK1 and ERα at promoters suggests that E2 signaling
causes the convergence of ERα and MAP kinase pathways at these particular regions.
Although it is well-known that E2 is a lipophilic compound, able to diffuse directly
into the nucleus to facilitate ER activation, it is also known that E2 can activate
cellular processes (e.g., kinase cascades) in the cytoplasm (“extra-nuclear” signaling)
mediated by membrane-associated ERs and other E2-activated proteins [reviewed in
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Figure 3.7 JNK1 binding correlates with ERα occupancy at target promoters.
(A) Heatmaps showing JNK1 and ERα ChIP-chip signals for the "JNK1 recruited"
genes from MCF-7 cells after a 45 min. treatment with E2. The promoters were
arrayed from -2200 to +500 bp relative to each TSS (x-axis). The genes in each
category (y-axis) are ordered from those with the 5'-most JNK1 peak to those with the
3'-most JNK1 peak. ERα heatmap is ordered according to JNK1 heatmap.
(B) Pearson correlation analysis of the JNK1 and ERα peak data from (A) shown as a
scatter-plot.
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Figure 3.8 ERα is bound at "JNK1-recruited" regions.
(A, B) ChIP-qPCR analyses of ERα binding at "JNK1-recruited" (A) and "JNK1released" (B) promoters in MCF-7 cells treated with ethanol (U) or E2 (E) revealed the
association of ERα with JNK1 recruited but not JNK1 released peaks. Each bar =
mean + SEM, n ≥ 2.
(C) ChIP-qPCR analysis of JNK1 and ERα for three previously identified ERαbound enhancer regions (Carroll et al., 2005) demonstrating that ERα / JNK1
complexes do not just occur at promoter regions. Each bar = mean + SEM, n ≥ 3.
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Figure 3.9 JNK1 recruited peaks have a peak profile similar to ERα.
(A) The average JNK1 and ERα ChIP signals from ChIP-chip (left) and ChIP-qPCR
(right) are shown for three "JNK1-recruited" promoters (GREB1, HOXC10, CYP1B1).
(B) Similar analysis as in (A) but for three “JNK1-released” promoters (CEP350,
CENPA, RNF167). ChIPs from MCF-7 cells treated with ethanol (U) or E2 (E). The
gray box indicates the regions of ChIP-qPCR; x-axis represents number of bp from the
TSS. Each bar = mean + SEM, n ≥ 2.
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Figure 3.9 (Continued)
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(Fu and Simoncini, 2008)]. These cascades could ultimately be responsible for the
JNK1 recruitment observed in the ChIP assays.
In order to determine the requirement of E2 signaling on JNK1 recruitment, I
performed ChIP assays using conjugated E2 derivatives, which can initiate
cytoplasmic but not nuclear estrogen signaling pathways (Harrington et al., 2006).
Indeed, treatment of MCF-7 cells with these compounds resulted in the rapid
phosphorylation of ERK demonstrating that the E2-conjugates, like E2, could initiate a
cytoplasmic response (Figure 3.10A). These reagents failed to promote the binding of
ERα, as expected, since they can not enter the nucleus (Figure 3.10B). Examination
of JNK1 occupancy revealed that, like ERα, the E2-conjugates could not induce the
binding of the MAP kinase to these regions (Figure 3.10C). These results suggest a
direct role for ERα at the sites of E2-dependent JNK1 recruitment.

Although

membrane-initiated estrogen signaling may contribute to the hormone-induced binding
of ERα and JNK1 to promoters, it is not sufficient to elicit the response alone.

Bioinformatics links specific transcription factors with JNK1 occupancy.
Because JNK1 does not bind to DNA directly, its association with DNA must be
facilitated by DNA-bound transcription factors (TF). I used a series of bioinformatic
analyses to determine which TFs might be facilitating the binding of JNK1 to the
promoter regions. First, I used MEME (Multiple Em for Motif Elicitation) and MAST
(Motif Alignment and Search Tool) (Bailey et al., 2006) in an unbiased search for
DNA sequence motifs enriched in JNK1-bound regions. These results yielded a
number of high confidence motifs for both the “JNK1 recruited” and “JNK1 released”
peaks, but notably did not include estrogen response elements (EREs) (Figure 3.11). I
then used TESS (Transcription Element Search System) to predict the TFs that might
bind to these enriched sequences.

The TF whose binding site had the highest
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Figure 3.10 Nuclear estrogen signaling is required for JNK1 recruitment to
target promoters.
(A) MCF-7 cells were treated with ethanol (U), 10 nM E2 (E), 10 nM E2-conjugated
BSA (E2-BSA), or 10 nM E2-dendrimer conjugate (EDC) for 10 min., followed by
Western blotting for ERK and phosphorylated ERK (P-ERK). The concentrations of
the estrogen derivatives were based on the amount of E2 in the conjugates, as
previously described (Harrington et al., 2006).
(B,C) The binding of ERα (A) and JNK1 (B) was determined by ChIP-qPCR at three
selected promoters after a 45 min. treatment as described in (A). Bars represent the
mean ChIP signal relative to the maximal E2 signal for each experiment, n ≥ 3. Error
bars = SEM for U, E2-BSA, and EDC.
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Figure 3.11 Unbiased bioinformatic analysis using MEME/MAST.
The DNA sequences from JNK1-bound regions (± 250 bp from the center of each
JNK1 peak) were analyzed using Multiple Em for Motif Elicitation (MEME) and
Motif Alignment and Search Tool (MAST) software (Bailey et al., 2006), as described
in the Materials and Methods. The results are divided into "JNK1-recruited" and
"JNK1-released" peaks. The p-values for enriched sequences were determined by a
Fisher exact test using the base count of motifs within peak regions versus those in
JNK1-negative regions. Motif predictions were examined by Transcription Element
Search System (TESS) (Schug, 2008) to determine the transcription factor most likely
to bind that sequence.

"Genes" represents the number of promoters where the

enriched sequence falls within 225 bp of the JNK1 peak. The JNK1 ChIP-chip
heatmap (JNK1) and the corresponding heatmap for the enriched sequence (Motif) is
shown for these promoters. The number of genes and the motif mapping refer to the
enriched sequences from MEME (not from mapping TRANSFAC weight matrices;
shown in subsequent figures).
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alignment score with the MEME motif was chosen as the best TF candidate. This
analysis identified AP-1, as well as other TFs not previously associated with JNK1
(Figure 3.11). These included the MADS box transcription factors MEF2 and SRF;
the POU homeodomain transcription factors (PIT-1) and POU3F3 (OCT7); and the
zinc finger transcription factor GATA-1.
Next, I mapped motif probability weight matrices for each of these
transcription factors [obtained from TRANSFAC (Wingender et al., 2001)] (Figure
3.12) to the JNK1 peaks. Selected TRANSFAC motifs were mapped across the
promoter regions present on the ChIP-chip array using MAST. Alignments with a pvalue < 1.5 x 10-4 were considered true motif calls, a threshold previously reported
(Kininis et al., 2007). Motifs that fell within 375 bp of a JNK1 peak were counted as
peak motifs and compared to the number of motifs outside of the peak regions.
Although EREs were not identified in the unbiased search, I also included an ERE
probability weight matrix in this directed search since I had already determined that
ERα was associated with JNK1 recruited peaks.

This analysis yielded high

confidence sites for all of the matrices searched (Table 3.2 and Figure 3.13A).
To test the validity of the bioinformatics analyses, I determined if the results
could be used to make accurate predictions about factor binding. For this analysis, I
focused on genomic regions containing high confidence AP-1 motifs (Figure 3.13 B
and C). Although “JNK1 recruited” regions showed E2-induced binding of JNK1 and
ERα, as expected (Figure 3.13D), only the regions with a high confidence AP-1 motif
showed binding of c-Fos, a component of the AP-1 heterodimer. Surprisingly, the
binding of c-Fos was also induced by E2 treatment (Figure 3.13D, bottom). Together,
these results support the validity of my bioinformatic analyses by demonstrating the
recruitment of JNK1 and c-Fos to regions containing predicted AP-1 sites.
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Factor

Weight Matrix

ID

AP-1

M00199

GATA-1

M00128

MEF2

M00006

POU3F2
(OCT7)

M00145

POU1F1
(PIT-1)

NA

NA

SRF

M00152

ERα

O’Lone et al.,
2004

Figure 3.12 TRANSFAC motifs used for motif mapping.
An unbiased bioinformatic analysis using MEME and TESS (Figure 3.11) identified
several putative transcription factors (TFs) as potential mediators of JNK1 binding.
The weight matrices for these factors (obtained from TRANSFAC) are shown with the
corresponding TRANSFAC ID or reference [the ERE sequence was previously
reported (O'Lone et al., 2004)]. The mapping of these matrices was used to define TF
binding sites used in subsequent analysis. Note, no weight matrix was available for
PIT-1.
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Table 3.2 Directed bioinformatic analysis of JNK1 Peak Regions
Factor

Matrix IDa

Genesb

p-valuec

AP-1

V$AP1_C

Recruited
Released

120
36

4.94 x 10-47
2.33 x 10-13

GATA-1

V$GATA1_04

Recruited
Released

188
42

<1.00 x 10-300
1.93 x 10-66

MEF2

V$MEF2_01

Recruited
Released

325
77

<1.00 x 10-300
3.94 x 10-141

POU3F2
(OCT7)

V$BRN2_01

Recruited
Released

209
53

<1.00 x 10-300
3.60 x 10-138

SRF

V$SRF_01

Recruited
Released

149
31

<1.00 x 10-300
3.23 x 10-48

ER

(O'Lone et al.,
2004)

Recruited

100

1.84 x 10-7

Released

35

2.78 x 10-5

Selected TRANSFAC motifs were mapped across the promoter regions present on the
ChIP-chip array using MAST. Motifs that fell within 375 bp of a JNK1 peak were
counted as peak motifs and compared to the number of motifs outside of the peak
regions.
a

The TRANSFAC IDs (or reference) for the weight matrices used in the analysis are
listed. The ERE sequence was previously reported (O'Lone et al., 2004).
b

"Genes" = the number of promoters that have the given motif within 375 bp of the
center of the JNK1 peak.
c

p-values were determined by Fisher's Exact Tests using the programming language
R, They were based on the probability of finding bases that compose the given motif
in a JNK1-bound region divided by the probability of finding bases that compose the
given motif in JNK1-absent regions.
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Figure 3.13 JNK1 peaks contain likely ERα tethering factor motifs.
(A) The results of the targeted search for transcription factor binding sites under the
JNK1-recruited regions is summarized (shown in Table 3.2). Motifs and their likely
associated binding factors were identified based on an initial unbiased search (Figure
3.11) and were mapped with MAST using position weight matrices from TRANSFAC
(Figure 3.12).
(B) The AP-1 motif from TRANSFAC is shown as a position weight matrix.
(C) Heatmaps showing the location of JNK1 binding (by ChIP-chip) and predicted
AP-1 binding sites (by MAST) for promoters containing an AP-1 motif within 225 bp
of a JNK1-recruited peak.
(D) ChIP-qPCR analyses of c-Fos binding at JNK1- and ERα-recruited regions before
(U) and after estrogen (E) treatment. UGT2B15, SPTBN4, TFF1 and GREB1 contain
at least one predicted AP-1 motif under the JNK1 peak. PLAC1 contains an ERE
sequence and is included (along with BLK44) as a negative control for c-Fos binding.
Mean ± SEM, n ≥ 3. Red lines represent background binding levels.
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JNK1 acts as a coregulator at E2-responsive genes.
Since JNK1 occupancy at genomic loci is affected by E2 signaling I wondered
if JNK1 might have a direct role in mediating E2-dependent transcriptional responses.
To this end, JNK1-depleted MCF-7 cells were generated by retroviral- mediated gene
transfer of a short hairpin RNA (shRNA) sequence targeting JNK1 mRNA. Two
different shRNA sequences gave similar levels of JNK1 mRNA and protein depletion
(results for one are shown, Figure 3.14A).

Control cells harboring an shRNA

sequence directed against GFP [described previously (Kim and Rossi, 2003)] were
generated in parallel. I examined the E2-dependent expression of target genes in
MCF-7 cells using reverse transcription-qPCR (RT-qPCR). Stable short hairpin RNA
(shRNA)-mediated knockdown of JNK1 or chemical inhibition of JNK catalytic
activity using a JNK-specific ATP competitor, SP600125 (Bennett et al., 2001),
inhibited the E2-stimulated (or E2-repressed) expression of some, but not all, estrogen
target genes (Figure 3.14 B and C). Although “off-target” effects can occur when
using chemical inhibitors in vivo, I believe that the SP600125 effects (Figure 3.14 B
and C) represent specific JNK inhibition since they agree so strongly with the JNK1
knock-down data for the same genes. Thus, JNK1 and its kinase activity are required
for full E2-dependent regulation of estrogen target genes in MCF-7 cells implicating
JNK1 as a hormone-dependent transcriptional coregulator of ERα.

E2-dependent growth of breast cancer cells requires JNK1.
As stated above, JNK1 expression is elevated in breast cancer carcinomas
relative to healthy breast tissues. One implication from this correlation would be that
elevated JNK1 levels provide a proliferative advantage to hormone-dependent tissues
like the breast. JNK1 is required for full E2-responsiveness at target genes, but does it
affect other E2-regulated outcomes, such as cell growth? Along these lines, I tested
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Figure 3.14 JNK1 activity is required for full estrogen-dependent transcriptional
responses.
(A) Analysis of JNK1 mRNA and protein levels in MCF-7 cells stably expressing
control (GFP) and JNK1 shRNA.
(B) The transcriptional response of E2-regulated genes from MCF-7 cells treated ± E2
for 3 hrs was determined by RT-qPCR. The effect of JNK1 knockdown (Top) or the
effect of the JNK inhibitor SP600125 (SP) (Bottom) on E2-regulated, JNK1 recruited
genes is shown. Asterisks represent p-values <0.05 (*) or <0.01 (**) (Student’s t-test)
versus E2 control (E; black bars). The E2-regulation of HOXC10 is not affected by
JNK1 knock-down or chemical inhibition. Mean ± SEM, n ≥ 3.
(C) E2-dependent down-regulation of gene expression also requires JNK1 activity as
the JNK inhibitor impairs E2-dependent repression of target genes. MCF-7 cells
treated as in (B) Expression data for GOLGB1 was from 6 hrs E2 treatment. Each bar
= mean ± SEM, n ≥ 2. Raw expression data from independent experiments were
normalized to ACTB expression; the untreated control condition was set to 100.
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Figure 3.14 (Continued)
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my JNK1 knock-down line to determine if the loss of JNK1 affected the growth of
these hormone stimulated breast cancer cells. Indeed, JNK1 knock-down resulted in
the loss of E2-stimulated growth while the GFP knock-down responded to hormone as
expected (Figure 3.15). This evidence, along with the role of JNK1 as a hormonedependent transcriptional coregulator of ERα, suggests a physiological link between
estrogen and JNK1 signaling at the genomic level with cell growth outcomes. This
link may have relevance for the growth and clinical outcomes of estrogen-dependent
breast cancers.

Discussion
Collectively, my results characterize the functional interplay between the
estrogen and MAPK signaling pathways that has been observed previously (Lange,
2004; Smith, 1998). This association is manifested in an extensive and unexpected
molecular crosstalk at the genomic level.
I demonstrated that JNK1 binds to specific sites in the genome. This illustrates
the fact that signaling molecules, like MAP kinases, associate with chromatin-bound
complexes broadening the understanding of how and where these kinases
phosphorylate their substrates. An even more amazing finding was that E2 treatment
caused a nearly complete redistribution of the JNK1 promoter localization pattern
(97% of the peaks changed) (Figure 3.4). This redistribution was not due to the net
movement of JNK1 to or from the nuclear compartment, nor was it due to a net change
in the phosphorylation status of JNK1 (Figure 3.3). These facts are in agreement with
each other since the phosphorylation of JNK is tightly linked to its nuclear
translocation (Gonzalez et al., 1993; Lenormand et al., 1998).

Cytoplasmic E2

signaling was not sufficient for the recruitment of JNK1 to E2-induced promoters
(Figure 3.10). Together, these data highlight the fact that the E2-dependent, genomic
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Figure 3.15 JNK1 is required for E2-induced proliferation in MCF-7 cells.
Cells expressing a shRNA construct for GFP or JNK1 were grown for 2 days in E2free media before being plated at equal densities and treated with ethanol or E2 (100
nM; E).
(A) Cells were counted 2 and 4 days after E2 addition.
(B) The average E2-dependent fold in proliferation for day 4 is shown. Bars equal the
mean ± SEM, n ≥ 2.
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changes of JNK1 occupancy involve the activated, nuclear pool of JNK1. The E2independent activation (and thus translocation) of JNK has no doubt played a role in
keeping the hormone-dependent crosstalk between these pathways enigmatic to date.
My investigation into the E2-modulated binding of JNK1 at target genes led to
the discovery that JNK recruited but not JNK released peaks correlated with ERα
binding (Figure 3.7-9). This suggests that at least two modes of hormone signaling
influence the genomic occupancy of JNK1.

Bioinformatic analyses determined

several transcription factors as likely JNK1-tethering factors. It is interesting to note
that due to the strong correlation between JNK1 and ERα at JNK1 recruited regions,
the TFs associated with these JNK1 complexes are also implicated in mediating ERα
complexes. Indeed, ERα exhibits two distinct modes of genomic binding: direct
binding to DNA containing ERE sequences and indirect binding or tethering through
other DNA-binding transcription factors, such as activator protein-1 (AP-1, a
heterodimer of c-Fos and c-Jun or related proteins) (Kushner et al., 2000).

My

analysis identified E2 recruited JNK1 and ERα complexes at promoters containing
EREs, but implied that this was not the major mode of JNK (and ERα) recruitment.
EREs represented only ~10 percent of all the sites identified (100 out of 1091 sites for
the JNK1-recruited peaks (Table 3.2 and Figure 3.13A). These bioinformatic results,
together with the ChIP-chip results described above, suggest that the E2-dependent
recruitment of JNK1 occurs primarily, but not exclusively, through an ERα tethering
mechanism mediated by diverse types of DNA-binding transcription factors.
I further demonstrated that JNK1 can act as a coregulator of ERα-dependent
transcriptional outcomes in a manner that requires its catalytic activity. The genespecific impairment of E2-dependent transcriptional responses by JNK1 knock-down
was mirrored in the loss of E2-stimulated growth in the JNK1 shRNA expressing line.
It is quite interesting to note that these effects are mediated specifically by JNK1
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despite the presence of the highly redundant MAPK, JNK2 (note that JNK2 expression
actually increased with JNK1 knock-down) (Figure 3.16).

Together, these data

suggest that the specific E2-regulated genomic activities of JNK1 can ultimately affect
hormone-dependent cellular processes. Indeed, JNK activity is important in tumor
growth and development as several studies have demonstrated the role of JNK in Rasmediated tumoricity [reviewed in (Davis, 2000)] and in oncogene activation [reviewed
in (Ip and Davis, 1998)]. Estrogen signaling may play a large role in these JNKdependent processes since JNK1 expression is elevated in breast carcinomas (Figure
3.1).

In addition, the expression of the JNK1 phosphatase, MPK-1, a negative

regulator of JNK1 activity, is reduced in high grade malignant breast cancers (Figure
3.17).
These results support a model for the estrogen- and ERα-dependent
recruitment of pre-activated JNK1 from the nuclear compartment (i.e., nucleoplasm or
chromatin) to the promoters of estrogen target genes.

JNK1, in turn, serves a

coregulator function required for efficient estrogen-dependent transcription of these
genes. This role of JNK1 in the genomic estrogen signaling pathway is supported by
JNK1's kinase activity, which likely targets histones or other proteins in the promoterassembled transcription complexes (claims supported by the work presented in
Chapter 4) (Figure 3.18).

In sum, my studies have identified a genomic nexus

between the estrogen and JNK1 signaling pathways that regulates target gene
expression and downstream cell growth responses.

Similar genomic systems are

likely to integrate the signaling pathways for other steroid hormones and signalregulated nuclear kinases. Future studies will aim to define the E2-regulated targets of
JNK1 and determine the molecular mechanisms of JNK-dependent phosphorylation in
mediating E2-regulated outcomes.
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Figure 3.16 JNK2 expression is regulated by JNK1.
JNK2 expression in MCF-7 cells stably expressing an shRNA to GFP or JNK1 was
determined by RT-qPCR. Raw expression data from independent experiments were
normalized to ACTB expression and expressed relative to the GFP shRNA sample.
Each bar = mean + SEM, n = 4.
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Figure 3.17 Expression of the JNK phosphatase, MKP-1, decreases with breast
cancer progression.
The relative expression of MKP-1 across three breast carcinoma grades is shown from
five independent studies (Bittner, 2005; Desmedt et al., 2007; Ivshina et al., 2006;
Miller et al., 2005; Sotiriou and Desmedt, 2006).

The p-values for negative

correlation was <0.001 for all five studies. The values were normalized so that the
average expression level for the Grade 1 sample from each study was 1. Red bars
represent the average signal in each category.
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Figure 3.18 JNK1 is an estrogen-dependent coregulator.
A model illustrating the estrogen-dependent regulation of JNK1 localization at
promoters, including features described in Chapter 4 (i.e., JNK1 phosphorylation
targets), is shown. Activated (phosphorylated) JNK1 is co-recruited with ERα to
promoters containing certain transcription factors, such as AP-1.

JNK1 then

phosphorylates transcriptionally relevant targets, such as H3 or coactivators of ERα,
allowing full E2-responsiveness at the given promoter.
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Materials and Methods

Cell culture.

MCF-7 cells were maintained in MEM with Hank’s salts

(Sigma; M1018) supplemented with 5% calf serum, sodium bicarbonate,
penicillin/streptomycin, and gentamicin. Prior to all experimental procedures and
treatment with control vehicle (ethanol) or E2 (100 nM), the cells were grown for at
least 3 days in phenol red-free MEM Eagle modified, with Earle's salts (Sigma;
M3024) supplemented with 5% charcoal-dextran calf serum, L-glutamine, sodium
bicarbonate, penicillin/streptomycin, and gentamicin.

For the JNK inhibition

experiments, the cells were treated with 20 µM SP600125 (SP) (BIOMOL) for 10 hrs
before treatment with E2.

Antibodies.

The antibodies used are as follows:

JNK1 (Santa Cruz, sc-474),

phosphorylated JNK (Santa Cruz, sc-6254), JNK (Santa Cruz, sc-7345), c-Fos (rabbit
polyclonal generated in the Kraus lab), ERα (rabbit polyclonal generated in the Kraus
lab), ERK (Santa Cruz, sc-154), phosphorylated ERK (Cell Signaling, 9106L),
GAPDH (kindly provided by Eric Alani, Cornell University).

Preparation of cell extracts.
• JNK1 localization: Estrogen-starved MCF-7 cells were treated with ethanol
or 100 nM E2 for 45 min.., washed with ice-cold PBS, released by scraping, and
collected by centrifugation. The cell pellets were resuspended in hypotonic buffer (10
mM Tris•HCl pH 7.9, 10 mM NaCl, 3 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 5 mM
NaF, 1 mM sodium vanadate, 4 µg/ml aprotonin, 4 µg/ml leupeptin, 1 mM DTT, 1
mM PMSF), incubated on ice for 10 min., and homogenized by Dounce 40 times with
a tight glass pestle. The lysate was centrifuged at 8,000 rpm in a microfuge at 4°C and
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the supernatant was collected as the cytoplasmic fraction. The nuclei were washed
twice with hypotonic buffer + 0.1% NP-40 and resuspended in hypertonic buffer (10
mM Tris•HCl pH 7.9, 420 mM KCl, 10% glycerol, 10 mM NaCl, 3 mM MgCl2, 1
mM EDTA, 1 mM EGTA, 5 mM NaF, 1 mM sodium vanadate, 4 µg/ml aprotonin, 4
µg/ml leupeptin, 1 mM DTT, 1 mM PMSF). After a 10 minute incubation on ice, the
extracted nuclei were pelleted by centrifugation as above and the supernatant was
collected as the nuclear fraction. The protein concentration for both fractions was
determined by Bradford assays.

• Detection of Activated ERK: Estrogen-starved MCF-7 cells were grown for
24 hrs in serum-free medium, followed by a 10 min. treatment with ethanol, 10 nM
E2, 10 nM 17β-estradiol 17-hemisuccinate:BSA (E2-BSA) (Steraloids), or 10 nM
estrogen-dendrimer conjugate (EDC) (Harrington et al., 2006) (kindly provided by
John Katzenellenbogen, University of Illinois, Urbana-Champaign). The cells were
washed with ice-cold PBS, released by scraping, and collected by centrifugation. The
cell pellets were resuspended in lysis buffer (50 mM Tris•HCl pH 7.9, 500 mM NaCl,
1 mM EDTA, 10% glycerol, 1% Triton X-100, 0.1% SDS, 5 mM NaF, 1 mM sodium
vanadate, 4 µg/ml aprotonin, 4 µg/ml leupeptin, 1 mM DTT, 1 mM PMSF) and
subjected to three freeze-thaw cycles using liquid nitrogen. Lysates were collected
after maximum centrifugation in a microfuge at 4°C. Protein concentrations were
determined by Bradford assays.

Immunofluorescence. Estrogen-starved MCF-7 cells were grown on coverslips and
treated with ethanol or 100 nM E2 for 45 min. After a wash with PBS, the cells were
crosslinked on the coverslips for 10 min. at room temperature with a formaldehyde
solution (3% formaldehyde, 5% sucrose in PBS) and the reaction was stopped by
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addition of 125 mM glycine. The cells were rinsed twice with PBS, permeablized for
15 min. with 0.1% Triton X-100 made in PBS, and blocked for 20 min. with 5% BSA
made in PBS. The cells were washed two more times with PBS and incubated for 30
min. with a JNK1 antibody (1:250 dilution with PBS). Afterwards, the cells were
washed 3 times with TBST (10 mM Tris•HCl pH 7.9, 150 mM NaCl, 0.05% Tween20) and incubated with a fluorescein-conjugated secondary antibody (Jackson; 115095-146) (1:1000 dilution with PBS) for 30 min.. The coverslips were then washed 5
times with TBST, mounted to slides using Vectashield (Vector Laboratories; H-1000),
and visualized using a Leica Confocal Microscope System.

Chromatin immunoprecipitation (ChIP). ChIP assays were performed as described
previously (Kininis et al., 2007), with minor modifications . The cells were grown to
~80% confluence and treated with ethanol or 100 nM E2 for 45 min. The cells were
then crosslinked with 10 mM dimethyl suberimidate•HCl (DMS; Pierce, 20700) for 10
min. at room temperature, followed by 1% formaldehyde for 10 min at 37°C, with
subsequent quenching by 125 mM glycine for 5 min. The crosslinked cells were
collected by centrifugation, resuspended in lysis buffer [0.5% SDS, 10 mM EDTA, 50
mM Tris•HCl pH 7.9, 1x protease inhibitors (Roche; 1836153)], and sonicated three
times for 10 seconds using a Branson Digital Sonifier at 27% power. This resulted in
DNA fragments of ~500 bp as determined by agarose gel electrophoresis. Cell debris
was removed by centrifugation and the remaining lysate was diluted 10-fold using
dilution buffer (1.1% Triton X-100, 1.2 mM EDTA, 17 mM Tris•HCl pH 8.0, 167 mM
NaCl, 1x protease inhibitors). After a 1 hr pre-clearing step using protein G-agarose
beads (Invitrogen; 15920-010), a portion of the lysate was collected as “input”
material, while the remaining lysate was incubated overnight with antibodies against
JNK1, ERα, c-Fos, or without antibodies as a control.
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The lysates were then

incubated with protein G-agarose beads for 4 hours to capture the immunoprecipiated
complexes. The beads were then washed three times with wash buffer (0.25% NP-40,
0.05% SDS, 2 mM EDTA, 20 mM Tris•HCl pH 8.0, 250 mM NaCl, 2 µg/ml leupeptin
and 2 µg/ml aprotinin) and once with TE. The immunoprecipitates were resuspended
in elution buffer (1%SDS, 100 mM NaHCO3) and incubated overnight at 65°C to
reverse the crosslinks. The proteins were digested for 45 min. at 37°C with 12.5 µg
proteinase K and the DNA was precipitated with ethanol/sodium acetate following an
extraction with phenol:chloroform:isoamyl alcohol. The DNA pellets were dissolved
in water and analyzed by qPCR. Before averaging, the ChIP values for each region
were normalized.

Each ChIP experiment was conducted with at least three

independent chromatin isolates to ensure reproducibility.

Ligation-mediated PCR (LM-PCR). For ChIP-chip analysis, immunoprecipitated
genomic DNA was blunted and amplified by LM-PCR as described previously
(Krishnakumar et al., 2008). The material was purified following digestion with
RNase (Roche) using QIAquick columns (QIAGEN). qPCR on selected regions was
used to confirm that the LM-PCR procedure preserved the binding patterns of the
initial immunoprecipitated material. The LM-PCR for the ChIP-chip experiments was
done using three independent ChIP experiments from cells treated with or without E2.

ChIP-chip. After LM-PCR, the immunoprecipitated material was labeled with Cy5
and the reference ("input") material was labeled with Cy3. The labeled samples were
combined and hybridized to human HG18 RefSeq Promoter Arrays (Nimblegen;
C4226-00-01).

Briefly, this array contains ~19,000 well-characterized RefSeq

promoters tiled with 50-mer to 75-mer probes every 100 bp. The tiled regions cover
~2200 bp upstream and ~500 bp downstream of each TSS.
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ChIP-chip data analysis.
• Moving window analysis: Data processing was done essentially as described
previously (Krishnakumar et al., 2008) using the statistical programming language R
(Team, 2006). All R scripts are available upon request. The pairwise data files
supplied by Nimblegen were used to calculate the log2 ratio data for each array. The
ratio values were subjected to lowess normalization and the arrays were normalized to
each other using equivalent sum of squares scaling. An error model was generated
using a 600 bp moving window with 150 bp steps in which both the mean probe log2
ratio and p-value were calculated for each window. The moving window analysis was
also performed on a composite fold array that represented the average JNK1 ratio in
the presence of E2 divided by the average JNK1 ratio in the absence of E2. All pvalues were calculated using a nonparametric Wilcoxon signed-rank test.

• Definition of significant bound regions: JNK1-bound regions were defined
as the windows containing: (1) positive means in all three biological replicates, (2) at
least 5 probes, and (3) p-values <0.05. Constitutive regions were defined as JNK1bound regions (present in the E2-treated and untreated samples) that did not have a
significant p-value (≥0.032) from the composite fold analysis. Recruited regions were
defined as JNK1-bound regions (present in the E2-treated samples) that had both a
significant p-value (<0.032) and a fold ratio >1. Released regions were defined as
JNK1-bound regions (present in the untreated samples) that had both a significant pvalue (<0.032) and a fold ratio <1. Of the defined regions, 98% of the recruited
regions and 95% of the released regions had an absolute fold change of ≥1.3.

• Visual representation of the data: The TSS-anchored heat maps used to
visualize the ChIP-chip data were generated with Java Treeview (Saldanha, 2004).
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For genes with multiple TSSs, the most 5’ TSS in a given tiled region was used for
alignment as +1.

Bioinformatic analyses.
• De novo motif prediction: Three gene lists were generated for de novo motif
predictions: (1) JNK1-recruited, (2) JNK1-released, and (3) JNK1-negative.

The

recruited and released lists report the 500 bp surrounding the location of the maximum
fold change (positive or negative) for the JNK1-recruited and JNK1-released genes,
respectively.

The JNK1-negative list reports the regions on the array with no

significant JNK1 signal. These lists were formulated using the tools on the Galaxy
browser (Elnitski et al., 2006) so genomic locations from JNK1-bound regions would
not be present in the background regions. Genomic sequences for all regions were
obtained from a local mirror of the UCSC genome browser, release HG18. JNK1negative sequences were extracted in the same manner and used to compute
background nucleotide frequencies and 1st- through 3rd-order Markov background
models.
De novo motif detection was carried out using MEME (Multiple Em for Motif
Elicitation) (Bailey et al., 2006) on repeat masked sequences, using the 3rd order
background model. A width range of 6 to 15 nucleotides was specified and any
number of sequence occurrences was allowed within peak regions. The top 20 motifs
in each peak class were retained for further analysis.

Motifs with a Pearson’s

correlation coefficient ≥ 0.6 were grouped as similar motifs and were represented by
the motif with the greatest MEME score. MAST (Motif Alignment and Search Tool)
(Bailey et al., 2006) was used to scan for the locations of all motif instances within
both bound and unbound sequences, using a p-value threshold of 1.5 x 10-4 as
previously reported (Kininis et al., 2007). Motifs were accepted as having a potential
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association with JNK1 binding only if they were significantly enriched within bound
peaks relative to background sequences. Fisher’s exact tests were used to determine
enrichments relative to background (heretofore generically referred to as “foreground”
and “background” classes) with p-values corrected for multiple testing using the Holm
method in R. Contingency tables were constructed based on the number of observed
motifs and total number of k-tuples in foreground and background sequences, where k
is the width of the motif.

• Assigning transcription factors to the predicted motifs:

TESS

(Transcription Element Search Software) (Schug, 2008) was used to predict the
transcription factors that might bind to the enriched sequences from MEME. Position
weight matrices for the predicted transcription factors (listed below with their
TRANSFAC identification tags) were obtained from the TRANSFAC database
(Wingender et al., 2001) and were converted to probability models. Pseudocounts
were introduced to avoid over-fitting the motif models, which were based on relatively
limited training datasets. The adjusted matrices for the predicted transcription factors
were mapped to the JNK1-bound and JNK1-negative regions with MAST using a 6th
order Markov model. Fisher's exact tests were used to determine the enrichments for
each motif, as described above. In addition, promoters were scanned for the presence
of EREs in the same manner and the enrichment calculated. The TRANSFAC
transcription factor motifs used for mapping are as follows: AP-1 (M00199), MEF2
(M00006), SRF (M00152), POU3F2/OCT7 (M00145), and GATA1 (M00128). The
ER motif was a consensus defined by O'Lone et al., 2004 (O'Lone et al., 2004).

Gene ontology.

Gene ontology (GO) analyses were performed using Genecodis

(Carmona-Saez et al., 2007). JNK1 gene sets (i.e., "JNK1-recruited", "JNK1-
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released") were uploaded and compared to the total gene list represented on the ChIPchip array. Search parameters included the following: (1) lowest GO level, (2) a
minimum of 5 genes per category, (3) each category represented by a single GO
identifier, false discovery rate (FDR) <0.01. P-values were calculated by Genecodis
using Chi-square tests. Ten randomly selected gene lists (5 of similar size to the
JNK1-recruited list, 5 of similar size to the JNK1-released list) were analyzed in a
similar manner to empirically determine the FDR. No GO terms were reported for
these random lists using the criteria above. Uninformative gene categories were not
recorded.

JNK1 knockdown. JNK1-depleted MCF-7 cells were generated by stable retroviralmediated gene transfer of a short hairpin RNA (shRNA) sequence specifically
targeting the JNK1 mRNA using the pSUPER.retro system under appropriate drug
selection (Oligoengine). Two different shRNA sequences, obtained from SuperArray
and cloned into the pSUPER vectors using unique EcoRI/XhoI sites, gave similar levels
of JNK1 mRNA depletion.

The JNK1 target sequences are as follows: 5’-

CAGAGAGCTAGTTCTTATGAA-3’ and 5’-CCTACAGAGAGCTAGTTCTTA3’. Control cells harboring a shRNA sequence directed against GFP were generated in
parallel The GFP target sequence used (5’-GAAGCTGACCCTGAAGTTCATC-3’)
was based on previous work (Kang et al., 2001).

Gene-specific expression analyses. The expression of endogenous target genes was
determined as described previously (Kininis et al., 2007), with minor modifications.
MCF-7 cells were grown to ~80% confluence and treated with ethanol or 100 nM E2
for 3 or 6 hours. Cells were washed with cold PBS and the total RNA was collected
using TRIZOL (Invitrogen) according to the manufacturer’s specifications.
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First

strand cDNA synthesis was performed using 2 µg of total RNA, 2 µg oligo(dT), and
600 units of MMLV reverse transcriptase (Promega). The resulting cDNA from each
sample was treated with 3 units of RNAse H (Ambion) for 30 min. at 37°C and then
diluted 1:5 with water. E2-treated samples were further diluted 1:10 and analyzed by
q PCR using a 96-well DNA Engine Opticon (MJ Research) or a 384-well Prism 7700
(ABI) real-time PCR thermocycler for 45 cycles (95°C for 15 sec, 60°C for 1 min)
following an initial 10 min. incubation at 95°C. The fold change in expression of each
gene was calculated using a standard curve of diluted cDNA from untreated samples
(1:1, 1:10, 1:100) and normalized against the fold change of β-actin, a wellcharacterized housekeeping gene that I used as an internal control.

Independent

experiments were scaled in relation to E2 expression levels with error bars
representing the SEM.

Primers for quantitative real-time PCR (qPCR).
The qPCR primers used for ChIP analyses are as follows:

ACO2 forward

5’- CTTGCACCAGGCCCGTCT -3’

ACO2 reverse

5’- AAGATGTTTTACCCAAGAACAAAT -3’

ACO2distal forward

5’- CTTCAGTCCTCTGCTATCTCCTG -3’

ACO2distal reverse

5’- CCAAGTTTTGTGATGCCAAG -3’

ADORA1 forward

5’- GCCTTGTGTCTGGATGATGTT -3’

ADORA1 reverse

5’- TCCCCAAACCACTGTACTCA -3’

Blk4 forward

5’-ATCCTTGATTTGGGGCAAT -3’

Blk4 reverse

5’- CTTGCAGGCCTCTCCTTCTA -3’

Blk42 forward

5’- GGCAGGCCAAACACACATG -3’

Blk42 reverse

5’- GCCCTGGACACAAACTGCAT -3’
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Blk44 forward

5’- GGGAAAATATGCAGAAGAAAACGA -3’

Blk44 reverse

5’- CATTTATTCAACACCTCTGATGTCCTA -3’

CENPA forward

5’- CCATCTCTGCGTTGCTAAGG -3’

CENPA reverse

5’- GTGCCCTCCAGTCAAAACAC -3’

CEP350 forward

5’- AGTGACAGCAGTGGGTAACG -3’

CEP350 reverse

5’- GGGGATTCGACAAGAATGAA -3’

CHPT1 forward

5’- TCTCTGAATCCGCAGTGATG -3’

CHPT1 reverse

5’- TCCCTTTCTGTACGGAGGAA -3’

CYP1B1 forward

5’- CGTGCGGCCTCGATTG -3’

CYP1B1 reverse

5’- AGGTGCCCACGTTTCCATT -3’

FLJ13305 forward

5’- GAAGGAGGGCGGTACATTCT -3’

FLJ13305 reverse

5’- CCAACTCTGGGCTTTTATTGG -3’

FLJ31818 forward

5’- ACAGCAGATGCCCTCAAGAA -3’

FLJ31818 reverse

5’- TCCAAATTAAAGGACAGGAGGT -3’

GOLGB1 forward

5’- ATGCTCCGCTTCCTCAAAG -3’

GOLGB1 reverse

5’- CCACTCGACACTTCCTGTCC -3’

GREB1 forward

5’- AGTGTGGCAACTGGGTCATTCTGA -3’

GREB1 reverse

5’- GGTATGATTCATCATTGTCTGCTGCG -3’

HDGF2 forward

5’- CCCCTTCACTCCCTTAGAGC -3’

HDGF2 reverse

5’- GAGGTTGGAGCACAGCAGTT -3’

HLA-DMA forward

5’- TTGCACATATACACACCACTCCT -3’

HLA-DMA reverse

5’- CTATCTCCTCCGCCTCCTCT -3’

HOXC10 forward

5’- AACGGTTTCGATCAAACTGGTGGG -3’

HOXC10 reverse

5’- AGCAGTCAATCCAGGGAGCCATTT -3’

HOXC10distal forward

5’- CCCTCCACCCCTCTACCTC -3’

HOXC10distal reverse

5’- AGTAACAGCGCCATCTAGCA -3’
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ITGA10 forward

5’- TCGTGTCCTCCATCCTGTCT -3’

ITGA10 reverse

5’- TCAGGTCCCCTCCTTATCCT -3’

KRT13 forward

5’- ACCCAGTATTAGAACGGGACCTGA -3’

KRT13 reverse

5’- TCCAGGACATCCCAGTCAGAAGTT -3’

OVOL2 forward

5’- TTGCCTCTCCTAACCACCCGAT -3’

OVOL2 reverse

5’- GCGGCTAGAAGATGTAGCCAATGT -3’

P2RX7 forward

5’- TGGAAGCTCCCAGTCTTGTGA -3’

P2RX7 reverse

5’- CACTTTTTTGGTCTCATGTCTCTTG -3’

PCYT1A forward

5’- CCCTCGCTGTCACTTACCA -3’

PCYT1A reverse

5’- GTTGCAGGTGTGTGCCTATC -3’

PDCD6IP forward

5’- TTCCTGATACTTTTTCCGTTTACC -3’

PDCD6IP reverse

5’- ACTACTGTTGACGGGCTGCT -3’

PLAC1 forward

5’- TGACAGAACTCATTCACAGGAAG -3’

PLAC1 reverse

5’- GGCAACAGCAAGCACTACAA -3’

PPM2C forward

5’- TTGGTGAACACTAGGGAAGATAAG -3’

PPM2C reverse

5’- GGCATTGGTATTGTCTGTGG -3’

PRUNE forward

5’- ACATACACATTTGTTTACCGAACGA -3’

PRUNE reverse

5’- TCCGCAATGTCCCTAGCAA -3’

RNF167 forward

5’- CCAGAGGGAGGAGAGGTTTG -3’

RNF167 reverse

5’- AGGTTAGCGATGGAGGGACT -3’

SERPINA1 forward

5’- TGGAGGAGGAATGAAGAAAGCA -3’

SERPINA1 reverse

5’- AGCAGGACCCCAAATTCTGA -3’

SLC27A2 forward

5’- CACGCCTGCAATATCTCCTTTAAT -3’

SLC27A2 reverse

5’- CACGGTTTCTTTAAATGGTGATGA -3’

SPTBN4 forward

5’- GACTACACGTGCGTGACACC -3’

SPTBN4 reverse

5’- ACGTCCCACACCCTATCGTA -3’
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TFF1 forward

5’- ATAACATTTGCCTAAGGAGGCCCG -3’

TFF1 reverse

5’- TCAGCCAAGATGACCTCACCACAT -3’

TFF1distal forward

5’- GGCCTGGTGTCCTCTGTG -3’

TFF1distal reverse

5’- CCCCATTTTGATCCGAGAA -3’

UGT2B15 forward

5’- TGAACTGTACACACTAATTGGTGAGTCA -3’

UGT2B15 reverse

5’- TCGTGGTGCAAGTAATGTCTTCTAA -3’

The qPCR primers used for expression analyses are as follows:

ACTB forward

5’- AGCTACGAGCTGCCTGAC -3’

ACTB reverse

5’- AAGGTAGTTTCGTGGATGC -3’

ANK3 forward

5’- CGCTCCTTCAGTTCGGATAG -3’

ANK3 reverse

5’- TTCCCTTGTGAATGTTAGATGCT -3’

CEP350 forward

5’- AAAGTGGCCTTAGCTTTTTGC -3’

CEP350 reverse

5’- GAAGATGTAAGTTTGTATTTCTTGCAG -3’

ELOVL2 forward

5’- AGAGGGTGGTTCATGTTGGA -3’

ELOVL2 reverse

5’- CAAGGTGAGGATACCCCTGA -3’

FAM5C forward

5’- TTTACAGTGCTTTTGTGGAACAG -3’

FAM5C reverse

5’- TTGTCAGCAAGTTCATGTGTG -3’

GOLGB1 forward

5’- CATGGGAGGACAGCATCTTC -3’

GOLGB1 reverse

5’- GATCAAGGGCAAAAGCAAAG -3’

GREB1 forward

5’- GCCGTTGACAAGAGGTTC -3’

GREB1 reverse

5’- GGGTTGAGTGGTCAGTTTC -3’

HOXC10 forward

5’- GACACCTCGGATAACGAAGC -3’

HOXC10 reverse

5’- TTTCTCCAATTCCAGCGTCT -3’

MAPK8 forward

5’- CATCATGAGCAGAAGCAAGC -3’
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MAPK8 reverse

5’- GCTGCGCATACTATTCCTTG -3’

MAPK9 forward

5’- TCATCCTGGGTATGGGCTAC -3’

MAPK9 reverse

5’- CAATATGGTCAGTGCCTTGG -3’

NUAK1 forward

5’- CAGTCACACACGCTGCTCTT -3’

PLAC1 forward

5’- CAGTGAGCACAAAGCCACAT -3’

PLAC1 reverse

5’- AACCACAGGAAACAGGAAGC -3’
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CHAPTER 4
Determination of JNK1 Substrates Using an In vitro Kinase System
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Summary
JNK family members, like other MAP kinases, transduce cellular signals by
phosphorylating target proteins.

Identifying JNK substrates is critical to

understanding the mechanisms of JNK-mediated processes (i.e., transcriptional
responses, cell-growth outcomes). Using a candidate approach, I determined that
JNK1 can phosphorylate proteins associated with estrogen-dependent signaling. This
modification can occur in cis (e.g., SRC-1, p300) or in trans (e.g., Histone H3). These
novel JNK targets may be responsible for mediating JNK-dependent outcomes at
hormone-responsive genes.

Introduction
In my previous work (discussed at length in Chapter 3), I described a hormonedependent correlation between ERα and JNK1 occupancy at various promoter regions.
I further demonstrated at certain E2-regulated genes occupied by JNK1 that these
promoters require the catalytic activity of JNK1 to attain maximal hormone
responsiveness. The question then arises: “What are the targets of JNK1 activity that
might play a role in mediating E2-dependent transcriptional outcomes?” One way to
start addressing this question would be to show the in vivo association of known JNK1
targets at E2-regulated promoters containing JNK1. This method would most likely
be expensive and technically challenging (e.g., purchasing many antibodies and
working out the appropriate chromatin immunoprecipitation conditions). I decided to
use an in vitro kinase assay to determine if JNK1 could phosphorylate known
coactivators of ERα.
In order to conduct these kinase assays I needed purified JNK1 in its active
form and candidate substrates to test. A previous study reconstituted a MAP kinase
pathway in bacteria as a means to purify rat JNK2 (rJNK2) in its active form
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(Khokhlatchev et al., 1997).

They used a two-plasmid system that enabled the

expression of three kinases involved in the JNK pathway. A phosphorylation relay is
established whereby the first kinase, a MAP kinase kinase kinase (MAPKKK),
phosphorylates the second kinase, a MAP kinase kinase (MAPKK), which
phosphorylates the third kinase, a MAP kinase (MAPK) (Figure 4.1A). This signaling
cascade is initiated by the expression of a constitutively active MAPKKK (referred to
as MEKK-C since it is a carboxy-terminal fragment of MEKK1) expressed from a
low-copy plasmid.

The remaining two kinases are expressed from a high-copy

plasmid containing a different selectable marker. Isolation of the terminal MAPK is
facilitated by the use of a 6x Histidine tag (Figure 4.1B). The two-plasmid system
allows the removal of the upstream kinase (MEKK-C) if purification of inactive
MAPK is desired. In this study, I modify this system to purify recombinant human
JNK1 for use in my in vitro kinase assays.
I wanted to determine what factors, known to associate with ERα in a liganddependent manner, could serve as potential substrates of JNK1 activity. Coactivators,
like p300 and SRC-1 have already been implicated in the ER/AP-1 pathway and are
very good candidates as possible substrates for JNK1 activity (Cheung et al., 2005;
Feng et al., 2001; Teyssier et al., 2001). Having a better understanding of the JNK1
substrates involved in E2-dependent outcomes will help to further elucidate the
mechanisms surrounding hormone-dependent actions in vivo.

Results
JNKs can be purified in their active and inactive forms from bacteria.
Using the MAP kinase system previously established in Dr. Melanie Cobb’s
lab, I purified JNK2 in its active and inactive forms. After I replaced the rJNK2
sequence with that of hJNK1α1 (details described in Methods and Materials), I
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Figure 4.1

Schematic of plasmid system used to reconstitute MAP kinase

phosphorylation relay in E. coli.
(A) The phosphorylation cascade for MAP kinases involves at least three enzymes.
When activated, the MAP kinase kinase kinase (MAPKKK) phosphorylates a MAP
kinase kinase (MAPKK) which, in turn, phosphorylates a MAP kinase (MAPK). The
proteins representing these kinase tiers are shown in parentheses.
(B) By introducing these three factors into bacteria using a two-plasmid system,
activated (phosphorylated) MAP kinases can be purified. Note that only the final
MAPK is expressed as a 6xHis fusion protein.
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purified the active form of this enzyme as well (Figure 4.2A). As a test, I compared
the ability of my active and inactive rJNK2 to phosphorylate c-Jun, a well-known
substrate of JNK. As expected, only the rJNK2 that was purified using the complete
phosphorylation relay system resulted in the phosphorylation of c-Jun (Figure 4.2B).
Comparison of the active rJNK2 and active hJNK1α1 demonstrated that they both
phosphorylated c-Jun with similar efficiencies (data not shown).

JNK1 phosphorylates coactivators of ERα.
Now that I had an in vitro kinase assay established, I wanted to determine if
JNK1 could phosphorylate proteins likely to play a role in mediating E2-dependent
transcriptional outcomes in vivo. SRC-1 and p300 seemed to be good candidates for
analysis since they both associate with liganded ER (Davie and Chadee, 1998; Leo
and Chen, 2000; Narlikar et al., 2002). They also, like JNK1, associate with AP-1
proteins (Bannister et al., 1995; Lee et al., 1998). These coactivators have also been
implicated in the formation of E2-dependent complexes tethered to DNA through AP1 sites (Cheung et al., 2005; Feng et al., 2001).
I purified ERα, SRC-1 and p300 and determined if they were, indeed,
substrates of JNK1 phosphorylation. I noticed that p300 and SRC-1 were efficiently
modified by JNK1 while ERα was phosphorylated less efficiently by comparison
(note the film exposure times for autoradiography) (Figure 4.3A). While all three
proteins contain proline-directed serines or threonines, it is interesting to note that both
p300 and SRC-1 contain a JNK binding motif similar to the docking motif found in
the JNK-interacting proteins, glucocorticoid receptor (GR) (Bruna et al., 2003) and cJun (Dai et al., 1995) (Figure 4.3B). This further implicates these coactivators as
likely substrates of JNK1 in vivo. No JNK interaction motif was found in the ERα
sequence that most likely explains the lower efficiency of phosphorylation.
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Figure 4.2 Active, recombinant JNK can be purified from bacteria.
(A) Rat JNK2 was purified from E. coli using the two-plasmid system as previously
reported (Khokhlatchev et al., 1997). The rat JNK2 sequence was cloned out and
replaced with the human JNK1 sequence and then purified in a similar manner.
(B) An in vitro kinase assay, using purified JNK2, demonstrated that the active
enzyme (P-JNK2) could phosphorylate recombinant c-Jun. Purification of JNK2 from
bacteria lacking the upstream activator plasmid resulted in an inactive enzyme
(unphosphorylated JNK2) that was unable to phosphorylate the c-Jun substrate.
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Figure 4.3 JNK1 phosphorylates coactivators.
(A) Kinase reactions were conducted using recombinant JNK1 incubated with ERα
(160 nM), p300 (160 nM), or SRC1 (140 nM). Although phosphorylation of ERα was
detected, the coactivators SRC1 and p300 were substantially modified in comparison
(note the relative exposure times for each autoradiogram)
(B) The amino acid sequence of p300, SRC-1 and ERα were examined for a putative
JNK interaction domain (Dai et al., 1995; Gupta et al., 1996; Kallunki et al., 1996;
Yasuda et al., 1999). SRC-1 and p300 but not ERα had a motif similar to the JNKinteracting sequence in c-Jun. Taken together, this data points to SRC1 and p300 as
probable in vivo targets of JNK1 enzymatic activity. Key: + = basic amino acids; x =
any amino acid; T = Threonine; Φ = hydrophobic amino acids; R = Arginine; K =
Lysine; M = Methionine; V = Valine. Numbers represent the first amino acid position
in the motif.
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JNK1 phosphorylates H3.
Because recent evidence has implicated histones (Clayton and Mahadevan,
2003; Thomson et al., 1999) as well as co-regulatory proteins (Yang et al., 2003) as
targets of MAPK cascades, I wondered if histones might serve as targets for JNK1
phosphorylation. Using the in vitro kinase assay, I also determined that H3 was
phosphorylated by JNK1 (Figure 4.4). This modification was prevented when the
histone was incorporated into the chromatin context of a mononucleosome. The DNA
template used for the nucleosome assembly contained an AP-1 binding site flanking
the nucleosome positioning sequence. Interestingly, JNK1 was able to phosphorylate
nucleosomal H3 when recombinant AP-1 dimers (Figure 4.4; Figure 4.5A) were added
to the reaction. This mechanism of AP-1-dependent phosphorylation of H3 by JNK1
is most likely facilitated by the recruitment of JNK1 to the mononucleosome by DNAbound AP-1. Indeed, in vitro DNase I footprinting analysis demonstrated that the
recombinant AP-1 dimers could bind AP-1 sites even when they were assembled into
a nucleosomal array (Figure 4.5B). This strengthens the notion that the AP-1 factors
were most likely recruiting JNK1 activity to the mononucleosome template rather than
just altering JNK1 specificity by interactions in solution. Together, I demonstrated
that H3 phosphorylation by JNK1, though inhibited by nucleosomal structure, can
occur when JNK1 activity is targeted to the nucleosome by DNA-binding transcription
factors.

Discussion
JNK1 has recently been shown to play a role in E2-mediated transcriptional
outcomes. Not only is the enzyme recruited to E2-regulated promoter regions in a
hormone-dependent manner, but JNK enzymatic activity is also required for full E2
responsiveness at certain genes (discussed at length in Chapter 3). The goal of this
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Figure 4.4 JNK1 phosphorylates the nucleosomal histone H3.
Kinase reactions were conducted using recombinant JNK1 incubated with core
histones (140 ng) or core histones assembled into mononucleosomes by salt dialysis.
Although phosphorylation of H3 was detected, incorporation of H3 into the context of
a nucleosome prevented this modification.

Because the DNA template used for

mononucleosome assembly contained a flanking AP-1 binding site, we added
recombinant AP-1 (c-FOS/c-JUN heterodimers, 300 nM) to “target” JNK1 specifically
to the assembled template. As expected, JNK1 phosphorylates the AP-1 proteins quite
well (exposure length is 5% that for the H3 autoradiogram). In the presence of AP-1,
H3 phosphorylation was restored. Taken together, this data suggests H3 as a possible
in vivo target of JNK1 enzymatic activity, and demonstrates that JNK1 can
phosphorylate H3 incorporated into nucleosomes.
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Figure 4.5 Purified c-Fos/c-Jun dimers can bind TREs in a chromatin context.
(A) c-Fos and c-Jun heterodimers were purified as described previously (Ferguson
and Goodrich, 2001).
(B)

DNase I footprinting analysis of a chromatinized template [assembled as

previously described (Kraus and Kadonaga, 1999)] containing 5 TREs demonstrated
specific protection of TRE regions with the addition of the purified AP-1 dimers. Red
arrows point to regions of DNaseI hypersensitivity. Together, these features indicate
that the purified AP-1 heterdimers can bind TREs even when they are assembled in
the context of chromatin.
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study was to further define how the enzymatic activity of JNK1 might contribute to
E2-dependent outcomes at these promoters. I established an in vitro kinase assay using
activated JNK1 purified from bacteria.
Using a candidate approach, I focused my attention on the co-regulators SRC-1
and p300, wondering if these E2-dependent coactivators might serve as substrates for
JNK1. Indeed these proteins, as well as ERα, were phosphorylated by JNK1 in vitro.
Since SRC-1 and p300 have a putative JNK binding domain, similar to that found in cJun and other JNK substrates [reviewed in (Bogoyevitch and Kobe, 2006)], it is likely
that these proteins serve as bona fide substrates of JNK in vivo, although this has yet to
be determined. I believe that SRC-1 and p300 may require phosphorylation by JNK to
fully potentiate E2-dependent transcriptional responses.

This could be mediated

through the stabilization / formation of phosphorylation-dependent protein-protein
interactions, as proposed for CBP/p300 with AP-1 complexes (Arias et al., 1994).
JNK phosphorylation could also alter the coactivator complex activity (note that p300
has acetyltransferase activity), a mechanism previously described for the histone
acetyltransferase, ATF2 (Kawasaki et al., 2000). Although weakly phosphorylated, it
is possible that ERα, under certain conditions, would be an in vivo target for JNK.
Recent findings have demonstrated that other nuclear receptors [specifically GR,
androgen receptor (AR), retinoic acid receptor α (RARα), retinoid X receptor α
(RXRα), peroxisome proliferator-activated receptor γ1 (PPARγ1), and Nur77] are
targets of JNK suggesting that ERα may also be a bona fide substrate in vivo (AdamStitah et al., 1999; Bruna et al., 2003; Camp et al., 1999; Gioeli et al., 2006; Han et al.,
2006; Srinivas et al., 2005). These studies show that phosphorylation by JNK can
effect the nuclear export (e.g., AR, Nur77), degradation (e.g., RARα), or
transcriptional activity (e.g., PPARγ1) of nuclear receptors suggesting a similar
mechanism of action for ERs.
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It is also possible that none of these factors are modified by JNK1 in vivo, but
their interaction with the MAP kinase facilitates the phosphorylation of other local
JNK1 substrates. Indeed, recruitment of JNK by c-Jun facilitates the phosphorylation
and activation of JunD, which is unable to bind JNK by itself (Kallunki et al., 1996).
This demonstrates that JNK binding can target phosphorylation sites in trans, as well
as in cis.

In this regard, I have shown that JNK1 can phosphorylate H3 in a

nucleosome when locally recruited by AP-1 transcription factors.

This is quite

interesting since recent work has demonstrated the importance of H3 serine 10
phosphorylation in mediating transcriptional responses (Huang et al., 2006). Taken
together, my work has identified several new targets of JNK1 phosphorylation and
suggests that the local modification of these factors might play a role in E2-dependent
transcriptional outcomes. Future work will focus on the identification of the specific
amino acids in SRC-1, p300, and H3 that are phosphorylated by JNK1, and
demonstration of the significance of these modifications with regard to transcriptional
regulation in cells.

Methods and Materials

Plasmids. Plasmids for the MAP kinase purification system were obtained from Dr.
Melanie Cobb, University of Texas Southwestern Medical Center.

The NpT7-5

plasmid, containing rat JNK2 (rJNK2) and MEK4 was modified to replace the JNK2
sequence with that of human JNK1α1 (hJNK1α1). Briefly, the hJNK1α1 sequence (a
kind gift from Dr. Roger Davis, University of Massachusetts Medical School) was
amplified by PCR inserting an NcoI site and 6x histidine sequence upstream of the
JNK1 sequence and a ribosomal binding site (RBS) and NcoI site downstream of the
JNK1 sequence. The PCR primer sequences are as follows: 5’- CCAGCCATGGGCC
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ATCACCATCACCACATAGCAGAAGCAAGCGTGACAA-3’

and

5’-

CCAGCCATGGTCTCCTTTCACAGACAAGTGCGCCATCTGCGAGGTTTTCAC
TGCTGCACCTGTGCTA-3’. The NpT7-5 plasmid was digested with NcoI removing
the rJNK2 and RBS and ligated to the NcoI digested PCR product. The replacement
of rJNK2 with hJNK1α1 was confirmed by sequencing.

Purification of JNK. The rJNK2 was purified from bacteria as previously reported
(Khokhlatchev et al., 1997). The inactive enzyme was purified in the same manner
from bacteria lacking the plasmid containing the constitutively active MAPKKK
(pBB131 with MEKK-C). The purification of hJNK1α1 was similar to that of rJNK2
with two major modifications: (1) the final cation exchange chromatography was not
necessary since the initial purification procedure yielded pure protein, and (2) the final
dialysis buffer contained 150 mM NaCl instead of 50 mM NaCl.

In vitro kinase assay. Kinase reactions were conducted with recombinant rJNK2
(active and inactive) and hJNK1α1 using recombinant c-Jun as a substrate positive
control. Briefly, the purified JNK (25-300 nM) was incubated with various substrates
for 30 minutes at 30C in kinase buffer (25 mM HEPES pH 7.5, 10 mM magnesium
acetate, 50 µM ATP, 2 µCi γ-32P ATP). After the labeled proteins were resolved using
SDS polyacrylamide gel electrophoresis, the gels were dried on filter paper and the 32P
signal was detected using a phosphoimager system. The substrates tested are as
follows: core histones from HeLa cells (140 ng), salt-dialyzed mononucleosomes
(containing approximately 140 ng HeLa core histones) purified as described (Kim et
al., 2001), flag-tagged SRC1 (140 nM) purified as described (Thackray and Nordeen,
2002), flag-tagged ERα (160 nM) and His-tagged p300 (160 nM) were purified as
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described (Kraus and Kadonaga, 1998), and c-FOS/c-JUN dimers (300 nm, purified as
described (Ferguson and Goodrich, 2001)).

DNase I footprinting. DNase I primer extension footprinting was performed as
described previously (Cheung et al., 2002; Pazin and Kadonaga, 1998). Purified AP-1
proteins (c-Fos/c-Jun heterodimers;12-200 nM) were added after chromatin assembly
of the 5xTRE-containing DNA template was complete, followed by a 15 minute
incubation at 27C to allow interaction of the factors with the chromatin template.
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